CN101066264A - Solid olmesartan medoxmil dispersion and its prepn and medicinal application - Google Patents

Solid olmesartan medoxmil dispersion and its prepn and medicinal application Download PDF

Info

Publication number
CN101066264A
CN101066264A CN 200710112373 CN200710112373A CN101066264A CN 101066264 A CN101066264 A CN 101066264A CN 200710112373 CN200710112373 CN 200710112373 CN 200710112373 A CN200710112373 A CN 200710112373A CN 101066264 A CN101066264 A CN 101066264A
Authority
CN
China
Prior art keywords
olmesartan medoxomil
carrier material
sodium
solid dispersion
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200710112373
Other languages
Chinese (zh)
Inventor
杨喜鸿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 200710112373 priority Critical patent/CN101066264A/en
Publication of CN101066264A publication Critical patent/CN101066264A/en
Pending legal-status Critical Current

Links

Abstract

The present invention relates to solid medicine dispersion containing olmesartan medoxmil and one or composition of polyvinyl pyrrolidone, poloxamer, polyethylene glycol and other carrier material. The present invention solves the problem caused by the insolubility, low dissolution, etc of olmesartan medoxmil to raise quality of the corresponding medicine preparation. The present invention also relates to the preparation process and medicine application of solid dispersion containing olmesartan medoxmil and carrier material.

Description

Solid dispersion of olmesartan medoxomil and preparation method thereof and medicinal application
Technical field the invention belongs to the pharmaceutical technology field, relate to olmesartan medoxomil solid dispersion, and preparation method thereof with its application in medicine.
Background technology olmesartan medoxomil (Olmesartan medoxomil), chemical name is 4-(1-hydroxyl-1-Methylethyl)-2-propyl group-1-[4-[2-(tetrazole-5-yl) phenyl] phenyl] Methylimidazole .-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxy cyclopentenes-4-yl) methyl ester, molecular structural formula is as follows:
Figure A20071011237300091
Olmesartan medoxomil is a kind of new angiotensin-ii receptor inhibitor, and hydrolysis forms active acid type structure in vivo, by stoping Angiotensin II and AT1 receptors bind, vascular smooth muscle is loosened, thereby bring high blood pressure down.
Olmesartan medoxomil is a fat-soluble compound, water insoluble, when oral administration, because medicine insoluble in water, cause containing its active ingredient of olmesartan medoxomil ordinary preparation compositions and in water, be difficult for moistening and indiffusion, be easy in gastro-intestinal Fluid that crystallization or precipitation are separated out and can not stripping with the peroral dosage form of conventional pharmaceutical adjunct and disperse system preparation, its bioavailability about 26%, greatly influence the absorption and the utilization of medicine, deposited sharp unfavorable factor.
Olmesartan medoxomil is as the active ingredient of medicine, when it is made as medicinal preparation for oral administration, having only olmesartan medoxomil to be dissolved in or to be scattered in the water could absorb in gastrointestinal well, if can not be dissolved in or be scattered in the water, then absorption and the biological utilisation for it can seem very difficult, therefore, the wettability and the dissolubility of improvement olmesartan medoxomil are very important and significant.
Summary of the invention is because the water-insoluble of olmesartan medoxomil, therefore under the prerequisite of the chemical compound pharmacological properties that does not change it, improves the intermiscibility and the dissolution of it and water, is vital.
The inventor is by studying and putting into practice pleasantly surprisedly and find: olmesartan medoxomil is fat-soluble chemical compound, selects suitable carrier material, and olmesartan medoxomil is prepared as solid dispersion, can solve an above-mentioned difficult problem well.
On the one hand, the invention provides a kind of solid dispersion that contains olmesartan medoxomil and carrier material, and preparation method thereof, medicinal application;
On the other hand, the present invention also provide a kind of contain olmesartan medoxomil, carrier material and other pharmaceutical carrier solid dispersion, and preparation method thereof, medicinal application.
The inventor finds: work as polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, when one or more in the polyoxyethylene castor oil exist, can improve dissolution and the dissolubility of olmesartan medoxomil in water well, and within the specific limits, along with polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the amount of one or more in the polyoxyethylene castor oil increases, and the dissolution of olmesartan medoxomil and dissolubility also can further improve.Therefore, the present invention selects one or more carrier materials as the solid dispersion of olmesartan medoxomil in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil for use.
At first, should be noted that following definition is applicable to whole description of the present invention and claims:
(1) polyvinylpyrrolidone, claim polyvidone again, english abbreviation PVP, it is the homopolymer of l-vinyl-2-pyrrolidone, according to its molecular weight difference, different models is arranged, as K30, K32, K25, K29, K90, K17, C15, C30 or the like, " polyvinylpyrrolidone " of the present invention comprises the mixture of its all models and any different model, preferably uses K30, K25;
Poloxamer, English name Poloxamer is α-hydrogen-ω-hydroxyl poly-(oxygen second is rare) a-poly-(oxypropylene) b-poly-(oxygen second is rare) cBlock copolymer is the novel macromolecule non-ionic surface active agent of a class.According to its molecular weight difference, different models is arranged, as 188,407,124,128,108,237,338, or the like, " poloxamer " of the present invention comprises the mixture of its all models and any different model, the preferred model 188,407 of using has Pluronic F68 as 188 model trade names commonly used;
Polyethylene Glycol is the mixture that oxirane and water polycondensation form, and molecular formula is with HO (CH 2CH 2O) nH represents, wherein n represents the average of oxyethylene group, english abbreviation PEG, Polyethylene Glycol has various molecular weight and physical property, and under the normal temperature and pressure, molecular weight is that the Polyethylene Glycol of 100-700 is a liquid, molecular weight is that the Polyethylene Glycol more than 1000 is a solid, Polyethylene Glycol has very good hydrophilic, is a kind of pharmaceutic adjuvant commonly used on the pharmaceutics, safety non-toxic.Solid dispersion selectivity of the present invention uses normal temperature and pressure to be solid-state Polyethylene Glycol down, for example PEG1000, PEG1500, PEG2000, PEG3000, PEG4000, PEG5000, PEG6000, PEG7000, PEG8000, PEG9000, PEG10000, PEG15000, PEG20000 or the like, and above-mentioned any two or more mixture;
Polyoxyl stearate is a polyethylene glycol mono stearate, and molecular formula is with C 17H 35COO (CH 2CH 2O) nH represents that the normal temperature and pressure that the present invention selects for use for solid polyoxyl stearate class material, preferably uses polyoxyethylene stearate (40) ester, polyoxyethylene stearate (50) ester down, and n is about 40 or 50;
Sucrose fatty acid ester is called for short sucrose ester, it is the big compounds that sucrose and fatty acid response generate, belong to polyol-based non-ionic surfactant, according to different with the replacement number of fatty acid response generation ester, monoesters, diester, three esters and polyester are arranged, change substituted fatty acid and esterification degree, can obtain the sucrose fatty acid ester of different HLB values (5～18), sucrose fatty acid ester of the present invention comprise sucrose stearate, sucrose oleate, sucrose palmitate, Surfhope SE Cosme C 1216, Sucrose myristate etc. one or more;
Polyoxyethylene castor oil is made by Oleum Ricini and oxirane additive reaction, be nonionic surfactant, water soluble, ethanol etc. mainly contain polyoxyethylene (10) Oleum Ricini, polyoxyethylene (35) Oleum Ricini, polyoxyethylene castor oil, polyoxyethylene (60) Oleum Ricini, polyoxyethylene (100) Oleum Ricini, polyoxyethylene (150) Oleum Ricini, polyoxyethylene (200) Semen Ricini wet goods.
(2) " pharmaceutical composition " of the present invention is meant the semi-finished product that contain medicament active composition and pharmaceutic adjuvant composition, preparation, preparation compositions etc.
(3) " carrier material " of the present invention refers to form with olmesartan medoxomil the basic material or the pharmaceutic adjuvant of solid dispersion, comprises in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil one or more.
(4) " pharmaceutical carrier " of the present invention is meant in pharmaceutical preparation (or in compositions), except that the principal agent composition, can be used for diluting, the pharmaceutic adjuvant or the excipient of filling, bonding, disintegrate, lubricated, painted, seasoning, moistening etc., pharmaceutical carrier also can form the disperse system of olmesartan medoxomil solid dispersion or the solid dispersion of multicomponent system with " carrier material " described in (3).
(5) " solid dispersion " of the present invention is meant a kind of disperse system that exists with solid form that the medicine high degree of dispersion is formed in solid carrier (dispersion material), perhaps high degree of dispersion is in liquid-carrier and make the disperse system of solid preparation, the latter such as soft capsule.
First aspect contains olmesartan medoxomil and carrier material
Solid dispersion, and preparation method thereof, medicinal application
The invention provides a kind of solid dispersion of olmesartan medoxomil, contain olmesartan medoxomil and carrier material, described carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, wherein the quality ratio range of olmesartan medoxomil and carrier material is 1: (0.5～180), the polyvinylpyrrolidone of the olmesartan medoxomil of promptly per 1 gram and 0.5 to 180 gram, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more carry out proportioning and the solid dispersion that forms;
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～170);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～160);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～150);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (4～140);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (5～130);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (6～120);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (7～110);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (8～100);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (9～80);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (10～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～35);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～30);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～25);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～20).
For example, olmesartan medoxomil and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the quality proportioning of one or more in the polyoxyethylene castor oil is 1: 0.6,1: 0.8,1: 0.9,1: 1,1: 1.2,1: 1.3,1: 1.4,1: 1.5,1: 1.6,1: 1.7,1: 1.8,1: 1.9,1: 2,1: 2.2,1: 2.5,1: 2.8,1: 3,1: 3.5,1: 4,1: 4.5,1: 5,1: 5.5,1: 6,1: 6.5,1: 7,1: 7.5,1: 8,1: 8.5,1: 9,1: 9.5,1: 10,1: 11,1: 12,1: 13,1: 14,1: 15,1: 16,1: 17,1: 18,1: 19,1: 20,1: 25,1: 30,1: 35,1: 40,1: 45,1: 50,1: 55,1: 60,1: 65,1: 70,1: 75,1: 80,1: 90,1: 100,1: 110,1: 120,1: 130,1: 150,1: 180, or the like.The present invention defines olmesartan medoxomil and is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the quality ratio range of one or more in the polyoxyethylene castor oil, be based on the consideration of the factors such as medicinal application of improving olmesartan medoxomil dissolution and deliquescent percentage contribution and solid dispersion, if polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the consumption of one or more in the polyoxyethylene castor oil is very few, and the dispersion of olmesartan medoxomil in solid dispersion can not exclusively and improve its dissolution and dissolubility is not remarkable; If the consumption of one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil is too much, the content of dispersion of olmesartan medoxomil in dispersion is low and improve its dissolution and deliquescent percentage contribution is inconsiderable yet, also is unfavorable for application and the cost accounting of postorder when producing preparation compositions.
The present invention also provides five kinds of preparation methoies of the solid dispersion of olmesartan medoxomil and carrier material (one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil):
Method one. solvent method, this method comprises: get olmesartan medoxomil and carrier material, add solvent, in 20 ℃ to the solvent boiling point temperature range, stirring is dissolved or dispersed in the solvent olmesartan medoxomil and carrier material, from this mixture, remove behind the mix homogeneously and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, described solvent is selected from methanol, ethanol, in the acetone one or more.In above-mentioned preparation, remove and to desolvate and exsiccant method can be taked Rotary Evaporators to steam to remove, removes under reduced pressure, in the drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, heating, drying one or more.
Method two. fusion method, this method comprises: get carrier material, add olmesartan medoxomil in 50～90 ℃ after being heated to complete fusion, mix, after cooling is solidified it, pulverize, promptly obtain solid dispersion, wherein said chilling temperature is below 25 ℃, preferred below 0 ℃ (as-5 ℃,-10 ℃,-15 ℃,-18 ℃,-20 ℃,-25 ℃,-30 ℃ or the like), optionally can further solid dispersion drying under reduced pressure (comprising vacuum drying) be beneficial to pulverize and preserve, described carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more.
Method three. solvent-fusion method, this method comprises: get carrier material in 50～90 ℃ be heated to complete fusion after, add and use methanol, ethanol is or/and the solution of olmesartan medoxomil of acetone solution, mix, remove and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, in above-mentioned preparation, described remove desolvated and exsiccant method can be taked Rotary Evaporators to steam to remove, remove under reduced pressure, drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, in the heating, drying one or more.
Method four. polishing, this method comprises: get carrier material and olmesartan medoxomil, put in the mortar and grind, 100～600 rev/mins of rotating speeds, milling time 10～150min takes out, and crosses 80～200 mesh sieves, promptly get solid dispersion of the present invention, wherein said carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil.
Method five. polishing, this method comprises: olmesartan medoxomil and carrier material are made pastel with suitable liquid, pastel is ground, further remove and desolvate and drying, pulverize, promptly get the solid dispersion of olmesartan medoxomil and carrier material, wherein said liquid is selected from methanol, ethanol, in the acetone one or more, wherein said remove desolvated and drying can adopt and removes under reduced pressure, drying under reduced pressure (comprising vacuum drying), spray drying, lyophilization, fluid bed drying, heating, drying, air-dry or noble gas is dry or its combination in any method concentrates and dry, wherein said carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, described solvent is selected from methanol, ethanol, in the acetone one or more
In above-mentioned preparation method four and the method five, the mode of described grinding can be carried out in such as grinder, extruder, homogenizer or blade blender.
The above-mentioned preparation method of the present invention all can be with olmesartan medoxomil and described carrier material homodisperse, resulting solid dispersion, it is the pressed powder of high degree of dispersion, the olmesartan medoxomil high degree of dispersion is in carrier material, under the Action of Surfactant of carrier material, and carrier material has changed the gathering or the crystalline form of Olmesartan ester molecule, can make the dissolution and the dissolubility of olmesartan medoxomil significantly improve, the solid dispersion of olmesartan medoxomil and carrier material can be seen a kind of composition with pharmacologically active as, come useful in preparing drug formulations to seem very easy and be easy to guarantee the quality of pharmaceutical preparation with this solid dispersion, therefore, the solid dispersion that the present invention also provides olmesartan medoxomil and carrier material contains application in the pharmaceutical preparation of olmesartan medoxomil, the application in the hypertensive medicine of preparation treatment in preparation.
Can pass through the administration olmesartan medoxomil of the present invention of any appropriate and the solid dispersion of carrier material, but usually by oral or parenteral route.Use in order to carry out this class, the solid dispersion of olmesartan medoxomil and carrier material can be prepared as acceptable any pharmaceutical dosage form on the pharmaceutics by adding suitable pharmaceutical carrier, and but, the definite form of said composition depends on form of medication naturally.
When the above-mentioned olmesartan medoxomil and the solid dispersion of carrier material are used for the treatment of as active ingredient, can directly give the patient simple olmesartan medoxomil and the solid dispersion of carrier material, for example with solid dispersion with the form of powder or directly the fill capsulae vacuus to give the patient oral, but sign in the assurance of the multiformity and the medicament quality of pharmaceutical dosage form, usually all be form appearance with the pharmaceutical composition that contains conventional pharmaceutically suitable carrier, therefore, the present invention also provides a kind of pharmaceutical composition, contain solid dispersion of the present invention and pharmaceutically suitable carrier, wherein in unit formulation, the content of the olmesartan medoxomil that solid dispersion provided of olmesartan medoxomil is 1mg～100mg;
The content of preferred olmesartan medoxomil is 2mg～80mg;
The content of preferred olmesartan medoxomil is 5mg～60mg;
The content of preferred olmesartan medoxomil is 10mg～40mg;
The content of preferred olmesartan medoxomil is 20mg.Below for example 2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 60mg, 70mg, or the like.Above-described compositions, " unit formulation " is meant the medicament of every one preparation compositions or individual packaging, for example each tablet (comprises dispersible tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets etc.), each hard capsule (comprises gastric solubleness, enteric, the slow release hard capsule), each soft capsule (comprises gastric solubleness, enteric soft capsules), per 1 to 1000 pill (comprises drop pill, micropill, because of its volume little, so a number of any integer word is decided to be a unit in will per 1 to 1000), each bag granule, each bag dry suspension, each bag powder, each bottleneck clothes liquid agent, each bottle (or bag) injection, each bottle powder ampoule agent for injection, or the like.
Should be understood that, on the one hand, in olmesartan medoxomil of the present invention and carrier material of the present invention----polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil one or more, wherein said carrier material also can be regarded the pharmaceutical carrier of olmesartan medoxomil as, be this carrier be not the simple pharmaceutical carrier that mixes with olmesartan medoxomil on the meaning, but by the blend of unconventional technology with olmesartan medoxomil and described carrier material formation high degree of dispersion; On the other hand, will be clear that, pharmaceutically suitable carrier of routine of the present invention is meant in pharmaceutical preparation (or in compositions), except that the principal agent composition, can be used for diluting, the pharmaceutic adjuvant or the excipient of filling, bonding, disintegrate, promotion dissolving or stripping, lubricated, painted, seasoning, moistening etc.
But be suitable for oral, non-intestinal or topical and can be tablet, hard capsule, soft capsule, pill, granule, dry suspension, powder, oral fluid agent, injectable or infusion solution or suspension, suppository, lozenge and transcutaneous device like this by being mixed with compositions and they.The Orally administered composition compositions of preferred oral administration, particularly molding or solid is because they are more convenient for generally using.
According to the difference of pharmaceutical dosage form, optionally can also optionally contain other suitable pharmaceutical carrier, such as diluent, filler, disintegrating agent, surfactant, suspending agent, binding agent, lubricant, coloring agent, flavoring agent etc.Described " optionally containing " is meant and can selects wherein one or more, also can not select.
There is and contains excipient commonly used in oral administration with unit dose usually with tablet (ordinary tablet, dispersible tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, chewable tablet, special-shaped tablets etc.), capsule (hard capsule, soft capsule, enteric coated capsule etc.), granule, dry suspension, powder, pill (micropill, drop pill) and oral liquid (solution, suspension, emulsion agent), such as diluent, filler, disintegrating agent, surfactant, suspending agent, binding agent, lubricant, coloring agent, flavoring agent etc.
Used suitable filler or diluent comprise lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, or the like; Described disintegrating agent comprises sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, pregelatinized Starch, corn starch, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, or the like; Described surfactant comprises sodium lauryl sulphate, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), or the like; Described suspending agent includes but not limited to hydroxypropyl emthylcellulose, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose, or the like; Described binding agent comprises polyvidone, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like; Described lubricant comprises magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate, or the like.In addition, also can comprise pH value regulator or buffer agent, for example phosphate buffer, citric acid, sodium citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide, or the like; Also can comprise antiseptic, for example sodium benzoate, potassium sorbate, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, or the like; Also can comprise stabilizing agent and antioxidant, for example calcium disodium edetate, sodium sulfite, vitamin C, vitamin E, or the like; Also can comprise the taste regulator, for example maltose alcohol, steviosin, aspartame, fructose, sucrose, saccharin sodium, flavoring orange essence, strawberry essence, or the like; Also can comprise additive other routine, appropriate in addition.
Further, the present invention also provides the preparation of drug combination method of the solid dispersion that contains olmesartan medoxomil and carrier material, this method comprises the solid dispersion of olmesartan medoxomil and pharmaceutically acceptable, suitable pharmaceutical carrier fully is mixed and made into acceptable any pharmaceutical dosage form on the pharmaceutics, and preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, chewable tablet, special-shaped tablets etc.), hard capsule (comprises gastric solubleness, enteric, slow releasing capsule), soft capsule (comprises gastric solubleness, enteric soft capsules), drop pill, pellet, granule, dry suspension, powder, oral fluid agent (comprises solution, suspension, emulsion agent), injection (comprising powder ampoule agent for injection and injection) etc.Can mix by solid dispersion and pharmaceutically suitable carrier/fusion/fusion/dissolution olmesartan medoxomil, common method such as granulation, filling, tabletting/fill gelatine capsule, compacting/drip system soft capsule prepares solid oral composition.Can use the operation of fusion repeatedly to be distributed in the pharmaceutical carrier so that make the abundant mixing of active ingredient; When preparation hard gelatin capsule and tablet, can adopt fill gelatine capsule or tabletting after the wet granulation drying, also can adopt fill gelatine capsule or tabletting behind the dry granulation, also can be with direct fill gelatine capsule of the solid dispersion of olmesartan medoxomil and carrier material or tabletting; When the preparation soft capsule, the Polyethylene Glycol that the solid dispersion dissolving or the dispersion of olmesartan medoxomil and carrier material can be liquid state at normal temperatures is (as PEG300, PEG400, PEG600 etc.) or after forming liquid or soft plastic state mixture in the vegetable oil (as soybean oil, the corn wet goods) obtain soft capsule with the soft capsule material of gelatin environmental sealing; When the preparation drop pill, can with room temperature down for solid-state Polyethylene Glycol (as PEG3000, PEG4000, PEG6000, PEG8000 etc.), behind the poloxamer heating and melting, make solid dispersion dissolving or be dispersed in Polyethylene Glycol, the poloxamer, form behind the liquefied mixture with drip the system machine system of dripping and cool off after obtain drop pill; Perhaps will after dripping system machine system of dripping and cooling, obtain drop pill behind the solid dispersion heating and melting of olmesartan medoxomil and glyceryl monostearate, polyoxyl stearate.Certainly, in the above-mentioned preparation, optionally also can add other pharmaceutic adjuvant, as disintegrating agent, surfactant, lubricant etc.
It is also understood that when pharmaceutical dosage form is tablet or capsule, can be the film coating.Can give tablet coating (enteric coating or gastric solubleness film-coat) according to method well-known in the art, the material that is used for the film coating, comprise suitable coating materials, for example Opadry, hydroxypropyl methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, or the like; Also can comprise plasticizer, for example Polyethylene Glycol, triethyl citrate, or the like.The coating membrane color can be various, as orange colour, white, blueness or the like.
Preferred pharmaceutical dosage form is tablet (comprising dispersible tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, special-shaped tablets etc.), hard capsule (comprising gastric solubleness, enteric, slow releasing capsule), soft capsule (comprising gastric solubleness, enteric soft capsules), drop pill, pellet, granule, powder, oral fluid agent (comprising solution, suspension, emulsion agent), injection (comprising powder ampoule agent for injection and injection) etc.
Particularly, by adopting wet granulation or dry granulation to obtain granule or dry suspension behind the solid dispersion of olmesartan medoxomil of the present invention and the pharmaceutical carrier mix homogeneously, optionally further tabletting obtains tablet or the fill Capsules obtains capsule, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose includes but not limited to the following material as lubricant: magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate; Or
By obtaining dry suspension or powder behind the solid dispersion of olmesartan medoxomil and the pharmaceutical carrier mix homogeneously, optionally can further dry suspension or powder fill Capsules shell be obtained hard capsule, perhaps mix homogeneously obtains granule behind wet granulation or the dry granulation, to obtain hard capsule in the granule fill Capsules shell, wherein the solid medicinal carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose includes but not limited to the following material as lubricant: magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate; Or
By obtaining soft capsule with dripping to make to seal with soft capsule material compacting of gelatin or capsule material glue behind the solid dispersion of olmesartan medoxomil and the suitable pharmaceutical carrier mix homogeneously, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: Liquid Macrogol, PEG400, Macrogol 600, soybean oil, Semen Maydis oil, other vegetable oil, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), described " soft capsule material compacting or the capsule material glue system of dripping are sealed " is meant and adopts pressing or dropping preparation method to prepare soft capsule, pressing is meant that the liquid or soft plastic state content that adopts press will contain solid dispersion wraps up formation preparation of soft capsule method with the compacting of capsule material film, can be pressed into different shapes and content content with different moulds, usually seal the capsule preparation with rotating the continuously automatic soft capsule production machine of rolling capsule machine or punching type automatically, dropping preparation method is meant the method that is equipped with soft capsule by a making mechanism, at a certain temperature, generally remain on more than 45 ℃, it is biphase utilizing capsule material glue and liquid content, after making a certain amount of capsule material glue with quantitative liquid content parcel, splash into that (condensed fluid can be a liquid paraffin in the another kind of not miscible condensed fluid, methyl-silicone oil, vegetable oil, in the kerosene any one), behind the capsule material glue condensation by contact liquid, owing to surface tension effects makes it to solidify the spherical soft capsule of formation; Or
Because poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate also can be as the good substrate of preparation drop pill, by with olmesartan medoxomil and poloxamer, Polyethylene Glycol, glyceryl monostearate, after the solid dispersion melting mixing of polyoxyl stearate is even, or with olmesartan medoxomil and poloxamer, Polyethylene Glycol, glyceryl monostearate, after the mixture melting mixing of polyoxyl stearate is even, splash in the not miscible condensed fluid, shrink condensation and make drop pill, optionally drop pill can contain but be not limited to following material as disintegrating agent: sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, can contain but be not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), described condensed fluid includes but not limited to dimethicone, liquid paraffin, vegetable oil (as Semen Maydis oil), kerosene obtains the drop pill capsule in the capsulae vacuus of optionally can further drop pill being packed into; Or
By with the solid dispersion of olmesartan medoxomil and suitable pharmaceutical carrier melting mixing evenly after, splash in the not miscible condensed fluid, shrink condensation and make drop pill, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: cetomacrogol 1000, polyethylene glycol 1500, Macrogol 3000, Macrogol 4000, Polyethylene Glycol 5000, polyethylene glycol 6000, Polyethylene Glycol 7000, Polyethylene Glycol 8000, Polyethylene Glycol 9000, cetomacrogol 1000 0, poloxamer, stearic acid, sodium stearate, hydrogenated vegetable oil, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, described condensed fluid includes but not limited to dimethicone, liquid paraffin, vegetable oil (as Semen Maydis oil), kerosene obtains the drop pill capsule in the capsulae vacuus of optionally can further drop pill being packed into; Or
By with behind the solid dispersion of olmesartan medoxomil and the suitable pharmaceutical carrier mix homogeneously, make the solid preparation of spherical or near-spherical, perhaps with the solid dispersion of olmesartan medoxomil and suitable pharmaceutical carrier dissolving or molten being dispersed in the liquid medium, and its deposition is coated on the surface of celphere and forms micropill, wherein the solid medicinal carrier includes but not limited to the following material as disintegrating agent: sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth) obtains the drop pill capsule in the capsulae vacuus of optionally can further micropill being packed into; Or
By the solid dispersion of olmesartan medoxomil and water or aqueous liquid mixing are evenly formed oral administration solution or suspension; Or
By solid dispersion and suitable injection pharmaceutical carrier mix homogeneously with olmesartan medoxomil, can obtain injection by the injection preparation method, wherein pharmaceutical carrier includes but not limited to the following material as filler or excipient: water, mannitol, sorbitol, lactose, xylitol, fructose, dextran, glucose, sodium chloride.
Optionally, difference and the needs of guaranteeing the medicament quality according to pharmaceutical dosage form can also add other suitable pharmaceutic adjuvant in the above-mentioned preparation method.
Second aspect contains olmesartan medoxomil, carrier material and other is medicinal
Carrier solid dispersion, and preparation method thereof, medicinal application
On the other hand, the present invention also provides the solid dispersions technique of a kind of olmesartan medoxomil and described carrier material and other pharmaceutical carrier, wherein contain olmesartan medoxomil, carrier material and other pharmaceutical carrier, the quality ratio range of olmesartan medoxomil and carrier material is 1: (0.5～180), be that carrier material that the olmesartan medoxomil and 0.5 to 180 of per 1 gram restrains carries out proportioning and the solid dispersion that forms, described carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more;
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～170);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～160);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～150);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (4～140);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (5～130);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (6～120);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (7～110);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (8～100);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (9～80);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (10～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～35);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～30);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～25);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～20).
For example, olmesartan medoxomil and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the quality proportioning of one or more in the polyoxyethylene castor oil is 1: 0.6,1: 0.8,1: 0.9,1: 1,1: 1.2,1: 1.3,1: 1.4,1: 1.5,1: 1.6,1: 1.7,1: 1.8,1: 1.9,1: 2,1: 2.2,1: 2.5,1: 2.8,1: 3,1: 3.5,1: 4,1: 4.5,1: 5,1: 5.5,1: 6,1: 6.5,1: 7,1: 7.5,1: 8,1: 8.5,1: 9,1: 9.5,1: 10,1: 11,1: 12,1: 13,1: 14,1: 15,1: 16,1: 17,1: 18,1: 19,1: 20,1: 25,1: 30,1: 35,1: 40,1: 45,1: 50,1: 55,1: 60,1: 65,1: 70,1: 75,1: 80,1: 90,1: 100,1: 110,1: 120,1: 130,1: 150,1: 180, or the like.
Described other pharmaceutical carrier is such as diluent, filler, disintegrating agent, surfactant, suspending agent, binding agent, lubricant, coloring agent, flavoring agent etc.
According to the difference of pharmaceutical dosage form, optionally can optionally contain other suitable pharmaceutical carrier, such as diluent, filler, disintegrating agent, surfactant, suspending agent, binding agent, lubricant, coloring agent, flavoring agent etc.Described " optionally containing " is meant and can selects wherein one or more, also can not select.
Described suitable filler or diluent include but not limited to lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, or the like; Described disintegrating agent includes but not limited to sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, pregelatinized Starch, corn starch, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, or the like; Described surfactant comprises but is not limited to sodium lauryl sulphate, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), or the like; Described suspending agent includes but not limited to hydroxypropyl emthylcellulose, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose, or the like; Described binding agent includes but not limited to methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like; Described lubricant includes but not limited to magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate, or the like.In addition, also can comprise pH value regulator or buffer agent, for example phosphate buffer, citric acid, sodium citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide, or the like; Also can comprise antiseptic, for example sodium benzoate, potassium sorbate, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, or the like; Also can comprise stabilizing agent and antioxidant, such as but not limited to calcium disodium edetate, sodium sulfite, vitamin C, vitamin E, or the like; Also can comprise the taste regulator, for example maltose alcohol, steviosin, aspartame, fructose, sucrose, saccharin sodium, flavoring orange essence, strawberry essence, or the like.
Technical solution of the present invention has come down to provide with carrier material and other suitable pharmaceutical carrier and has formed binary vector or polynary carrier, forms the solid dispersion system of disperseing olmesartan medoxomil to reach.
Certainly,, optionally can also use additive other routine, appropriate or pharmaceutic adjuvant,, can be selected from water, ethanol, water-ethanol solution etc. as wetting agent according to the difference of pharmaceutical dosage form.
Further, the present invention also provides the above-mentioned olmesartan medoxomil that contains, the preparation method of the solid dispersion of carrier material of the present invention and other pharmaceutical carrier, it comprises olmesartan medoxomil, carrier material of the present invention and other pharmaceutical carrier fully are mixed and made into any pharmaceutical dosage form of acceptable on the pharmaceutics, and preferred pharmaceutical dosage form is that tablet (comprises dispersible tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, chewable tablet, special-shaped tablets etc.), hard capsule (comprises gastric solubleness, enteric, slow releasing capsule), soft capsule (comprises gastric solubleness, enteric soft capsules), drop pill, pellet, granule, dry suspension, powder, oral fluid agent (comprises solution, suspension, emulsion agent), injection (comprising powder ampoule agent for injection and injection) etc.
Pharmaceutical dosage form is relevant with the preparation method of selected pharmaceutical carrier and postorder.
Particularly, by with olmesartan medoxomil, carrier material is dissolved or dispersed in alcohol, in the alcohol-water solution, with this liquid mixture as wetting agent to the pharmaceutical carrier wet granulation, remove and desolvate and drying, make the granule or the dry suspension of dispersion, optionally further tabletting obtains tablet or the fill Capsules obtains capsule, wherein other pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose, described alcohol, alcohol-water solution comprises ethanol, methanol, ethanol-water solution, methanol-water solution, described remove desolvated and drying can adopt and removes under reduced pressure, drying under reduced pressure (comprising vacuum drying), spray drying, lyophilization, fluid bed drying, heating, drying, air-dry or noble gas is dry or its combination in any method concentrates and dry; Or
By with olmesartan medoxomil, carrier material and other pharmaceutical carrier are dissolved or dispersed in alcohol, in the alcohol-water solution, stir or fully grind the back and remove and desolvate and dry, with solid drying and the pulverizing that obtains, promptly obtain the dry suspension or the powder of dispersion, optionally further tabletting obtains tablet or the fill Capsules obtains capsule, wherein other pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose, described alcohol, alcohol-water solution comprises ethanol, methanol, ethanol-water solution, methanol-water solution, wherein said remove desolvated and drying can adopt and removes under reduced pressure, drying under reduced pressure (comprising vacuum drying), spray drying, lyophilization, fluid bed drying, heating, drying, air-dry or noble gas is dry or its combination in any method concentrates and dry; Or
By with olmesartan medoxomil, carrier material and other pharmaceutical carrier are dissolved or dispersed in Polyethylene Glycol or the vegetable oil, seal or the capsule material glue system of dripping is sealed and obtained soft capsule with the compacting of the soft capsule material of gelatin, other pharmaceutical carrier includes but not limited to the following material as disintegrating agent: sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), wherein Polyethylene Glycol includes but not limited to Liquid Macrogol, PEG400, Macrogol 600, vegetable oil includes but not limited to soybean oil, Semen Maydis oil; Or
By with olmesartan medoxomil, after carrier material and other pharmaceutical carrier melting mixing are even, splash in the not miscible condensed fluid, shrink condensation and make drop pill, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: cetomacrogol 1000, polyethylene glycol 1500, Macrogol 3000, Macrogol 4000, Polyethylene Glycol 5000, polyethylene glycol 6000, Polyethylene Glycol 7000, Polyethylene Glycol 8000, Polyethylene Glycol 9000, cetomacrogol 1000 0, polyoxyethylene stearate (40) ester, glyceryl monostearate, stearic acid, sodium stearate, hydrogenated vegetable oil, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), described condensed fluid includes but not limited to dimethicone, liquid paraffin, vegetable oil (as Semen Maydis oil), kerosene obtains the drop pill capsule in the capsulae vacuus of optionally can further drop pill being packed into; Or,
By with olmesartan medoxomil, behind carrier material and other pharmaceutical carrier mix homogeneously, be dissolved or dispersed in alcohol, in the alcohol-water solution, make the solid preparation of spherical or near-spherical and make micropill, perhaps with olmesartan medoxomil, carrier material is with other pharmaceutical carrier dissolving or be dispersed in alcohol, in the alcohol-water solution medium, and its deposition is coated on the surface of celphere and makes micropill, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth) obtains pellet capsule in the capsulae vacuus of optionally can further micropill being packed into.
Above-mentioned preparation contains in the preparation method of solid dispersion of olmesartan medoxomil, carrier material and other pharmaceutical carrier, described " carrier material " comprises and is selected from glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil one or more, and described " being scattered in alcohol, alcohol-water solution " is meant that material forms with homodisperse states such as suspension, suspension, emulsion, colloids in liquid medium.Should be appreciated that substance dissolves is the dispersity of topnotch in liquid medium, and dispersive states such as the suspension that forms, suspension, emulsion, colloid also are good dispersities in liquid is situated between.The inventor is by repeatedly experiment discovery, less and not simultaneously when the consumption of liquid medium, material is easy to form dispersion states such as suspension, suspension, emulsion, colloid, and the prepared solid dispersion that contains olmesartan medoxomil, carrier material and other pharmaceutical carrier accordingly and the difference of formulations prepared from solutions are little.
Optionally, can also add other suitable pharmaceutic adjuvant in the above-mentioned preparation method.
Though the invention describes olmesartan medoxomil be selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil one or more solid dispersion and the concrete related content of two aspects such as their preparation and medicinal application, also should be included within the scope of the invention conspicuous some modification of experienced technical staff in the art or the situation that is equal to.
Also should be noted that; the invention provides olmesartan medoxomil and polyvinylpyrrolidone; poloxamer; Polyethylene Glycol; glyceryl monostearate; polyoxyl stearate; sucrose fatty acid ester; the technology contents of two aspects of the solid dispersion of one or more in the polyoxyethylene castor oil; and define olmesartan medoxomil and polyvinylpyrrolidone pointedly; poloxamer; Polyethylene Glycol; glyceryl monostearate; polyoxyl stearate; sucrose fatty acid ester; the dose-effect scope of one or more in the polyoxyethylene castor oil; polyvinylpyrrolidone; poloxamer; Polyethylene Glycol; glyceryl monostearate; polyoxyl stearate; sucrose fatty acid ester; in the polyoxyethylene castor oil one or more can be regarded the dispersant and the chaotropic agent of olmesartan medoxomil as in solid dispersion (or preparation compositions); solubilizing agent; but polyvinylpyrrolidone no matter; poloxamer; Polyethylene Glycol; glyceryl monostearate; polyoxyl stearate; sucrose fatty acid ester; being with which kind of purpose and bearing which kind of task of in the polyoxyethylene castor oil one or more; as long as existing within the dose-effect scope that solid dispersion of the present invention limits of it all should be included within protection scope of the present invention.
Need to prove, in the preparation of tablet, especially in the preparation of dispersible tablet, the selection of disintegrating agent and use are very important, the key of dispersible tablet is its disintegration rate in water, so the selection of the disintegrating agent system in the tablet is extremely important, dispersible tablet provided by the present invention, at least a carboxymethyl starch sodium (CMS-Na) that is selected from of the disintegrating agent of choosing, low-substituted hydroxypropyl cellulose (L-HPC), sodium carboxymethyl cellulose (CMC-Na), crospolyvinylpyrrolidone (PVPP), cross-linking sodium carboxymethyl cellulose (cCMC-Na), crosslinked carboxymethyl fecula sodium (cCMS-Na), microcrystalline Cellulose (MCC), carboxymethylcellulose calcium (CMC-Ca); In preparation process, disintegrating agent is made granule with the prescription powder, is referred to as addition in the disintegrating agent; Disintegrating agent mixes the back tabletting and is referred to as the outer addition of disintegrating agent with dried granules.Add in the disintegrating agent and add the speed that all can influence the dispersible tablet disintegrate, can adopt interior addition, also can adopt outer addition, can also in add, add common use; interiorly add, when adding common use, disintegrating agent can be identical, also can be different.This kind tablet, easy disintegrating disperses, and helps the stripping and the diffusion of olmesartan medoxomil.
Also need to prove, in the preparation of micropill, celphere is meant the prefabricated profiled microspheroidal ball that does not contain the medicine active ingredient, it is a kind of intermediate pharmaceutic adjuvant, usually outward appearance is spherical shape, the adjuvant that is used for celphere mainly contains filler and binding agent, optionally also can add a certain amount of disintegrating agent, porogen, lubricant and surfactant etc., can not only improve its dissolving, disintegrate, the outward appearance rounding property, also can improve its further machinability, as coating, be easy to performances such as drying, celphere can be buied from the market with the product of pharmaceutic adjuvant, as sucrose-starch celphere (35 to 40 order), microcrystalline Cellulose celphere, sucrose celphere.Pellet or drop pill, specific surface area is big, easily disperses and contacts with water, helps the stripping and the diffusion of olmesartan medoxomil.Same, granule provided by the invention, dry suspension, powder because the medicine high degree of dispersion is easy to contact with water, help the stripping and the diffusion of olmesartan medoxomil.Soft capsule because content is liquid or soft plastic state, has been the pre-wetted state, be easier to aqueous dispersion with contact with water, stripping.
Pharmaceutical dosage form of the present invention, (comprise dispersible tablet as tablet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, chewable tablet, special-shaped tablets etc.), hard capsule (comprises gastric solubleness, enteric, slow releasing capsule), soft capsule (comprises gastric solubleness, enteric soft capsules), pellet, granule (comprises effervescent granule, enteric coated particles etc.), dry suspension, powder, oral fluid agent (comprises solution, suspension, emulsion agent), injection (comprising powder ampoule agent for injection and injection) etc., more than these pharmaceutical dosage forms " all on the books and describe in the Chinese pharmacopoeia at 2005 editions.
The implication of nouns such as diluent of the present invention, filler, disintegrating agent, surfactant, suspending agent, binding agent, lubricant, coloring agent, flavoring agent belongs to the pharmaceutics category, be that those skilled in the art are familiar with maybe should being familiar with, should be able to understand the intention of the inventor for these nouns.For example: flavoring agent can be understood that to cover the pharmaceutic adjuvant (or additive) of bitter taste of drug or improvement taste perception very easily, purposes such as accent is sweet such as reaching, acid adjustment, perfumery, good mouthfeel can allow the patient be easy to accept pharmaceutical preparation, as effervescent tablet, oral cavity disintegration tablet, chewable tablet, granule, dry suspension, powder, oral fluid agent.
In addition, " including but not limited to " of the present invention is meant and comprises in the concrete material that is outlined one or more, but also can be outline outside, those skilled in the art can predict and to obtain, play the material of effect same and effect, for example " vegetable oil includes but not limited to soybean oil; Semen Maydis oil " refers to comprise soybean oil and/or Semen Maydis oil, but also comprise in addition vegetable oil or the oils and fats of its extraction, as Oleum Arachidis hypogaeae semen, olive oil, Fructus Maydis oil, soybean salad oil, rape salad oil, the corn salad oil, Petiolus Trachycarpi oil, olive oil, Oleum Gossypii semen, Oleum sesami, Oleum Helianthi, chilli oil, Oleum Ricini, Oleum Brassicae campestris, oleic acid, ethyl oleate, hydrogenated vegetable oil, lecithin, fabaceous lecithin, plant embryo oil, Oleum Camelliae or the like.
Olmesartan medoxomil provided by the invention and one or more the solid dispersion that is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil, be off-white color or yellow-white powder, mobile good, stable in properties.Adopt differential scanning calorimetric analysis (DSC), X-ray diffraction analysis that the solid dispersion of prepared different quality proportioning is investigated.DSC result shows that the DSC absworption peak of olmesartan medoxomil concentrates on 180～182 ℃, and does not observe the fusing point peak of olmesartan medoxomil in the solid dispersion or do not have tangible fusing point peak; X-ray diffraction analysis is the result show, in the solid dispersion of olmesartan medoxomil and described carrier material, olmesartan medoxomil mainly is scattered in wherein with microcrystalline form or unformed state, has formed coprecipitate or eutectic mixture.
The solid dispersion of one or more in olmesartan medoxomil of the present invention and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil is used to prepare the pharmaceutical composition for the treatment of high blood pressure disease.Further, the solid dispersion of one or more in olmesartan medoxomil of the present invention and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil and preparation thereof, the application in the medicine of preparation treatment high blood pressure disease.
In addition, the solid dispersion of olmesartan medoxomil provided by the invention can be used as the principal agent composition, with other appropriate drug active ingredient, makes compound preparation; Perhaps olmesartan medoxomil and other appropriate drug active ingredient are made solid dispersion with carrier material of the present invention, the preferred hydrochlorothiazide of other appropriate drug active ingredient for example, hydrochlorothiazide has good pharmacology synergism as diuretic and olmesartan medoxomil.
Verify further that with following test one or more solid dispersion in olmesartan medoxomil of the present invention and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil is at the significant advantage of aspects such as the dissolubility of improving olmesartan medoxomil and dissolution.
One. water-soluble is relatively
Under the normal temperature and pressure, record the dissolubility of olmesartan medoxomil in water less than 0.01mg/ml;
The dissolubility of the solid dispersion of the solid dispersion of one or more in the olmesartan medoxomil of each ratio of the present invention and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil (in olmesartan medoxomil) is all greater than 0.4mg/ml;
As seen, the solid dispersion of olmesartan medoxomil of the present invention has very significant effect to the dissolubility raising of olmesartan medoxomil.
Two. the dissolution test is relatively
Modelling: the solid dispersion (1: 3.5) of getting olmesartan medoxomil, olmesartan medoxomil and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, polyoxyethylene castor oil, make basic adjuvant glue wafer with pregelatinized Starch, test respectively, relatively its dissolution.
Sample preparation: respectively with olmesartan medoxomil, olmesartan medoxomil and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the solid dispersion of polyoxyethylene castor oil (1: 3.5) is a principal agent, by every capsules is 30mg with the olmesartan medoxomil, with the carboxymethyl starch sodium is disintegrating agent (every capsules contains 8mg), make surfactant and chaotropic agent (every capsules contains 5mg) with Tween-80, with the magnesium stearate is lubricant (every capsules contains 3.5mg), with an amount of 50% ethanol is wetting agent, all the other are the filler adjuvant with the pregelatinized Starch, make the heavy 350mg of every capsules, wet method system granule, dry, granulate, the granule filling capsule, keep preparation technology identical, make olmesartan medoxomil respectively, olmesartan medoxomil and polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the capsule of the solid dispersion of polyoxyethylene castor oil (1: 3.5).
Stripping content assaying method: according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2005).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With acetonitrile-phosphate buffer (pH3.0～3.5) is mobile phase; Flow velocity 1.0ml/min; The detection wavelength is 248nm.Theoretical cam curve is pressed the olmesartan medoxomil peak and is calculated, and should be not less than 4000.
Get the capsule of above-mentioned preparation respectively, test according to dissolution method (two appendix XC of Chinese Pharmacopoeia version in 2005 three therapeutic methods of traditional Chinese medicine), with phosphate buffer 250ml is dissolution medium, rotating speed is that per minute 75 changes, operation in accordance with the law, in the time of 45 minutes, get solution 10ml and filter, get subsequent filtrate as need testing solution; Other gets the about 20mg of sharp olmesartan medoxomil reference substance, accurate claims surely, puts that to add mobile phase in the 100ml measuring bottle an amount of, dissolving, add the stripping medium again to scale, shake up, precision is measured 1ml, put and add the stripping medium in the 100ml measuring bottle, shake up, in contrast product solution to scale.Precision is measured each 20 μ l of above-mentioned two kinds of solution and is injected chromatograph of liquid, and the record chromatogram by the external standard method stripping quantity, and calculates its dissolution.
The dissolution determination result (meansigma methods) and the relative standard deviation (RSD) of capsule sample see the following form.
Dissolution determination result (n=8) table 1
Figure A20071011237300261
Above table 1 measurement result explanation, in olmesartan medoxomil capsule and the solid dispersion body capsule, the capsular dissolution of solid dispersion very remarkable (P＜0.001) is better than the olmesartan medoxomil capsule.
Same, in above-mentioned model prepare olmesartan medoxomil and carrier material 1: 0.8,1: 1,1: 2,1: 3,1: 4,, the capsule of the solid dispersion of 1: 5,1: 6,1: 7,1: 8,1: 10,1: 20,1: 50,1: 80,1: 100,1: 130,1: 170 ratio, its dissolution also all is better than the olmesartan medoxomil capsule.
The specific embodiment in implementation process of the present invention, various embodiments that those skilled in the art produce on the basis that does not depart from the scope of the present invention with spirit and modify conspicuous and be to carry out easily.Come the present invention done further specifying by the following examples, but do not represent the embodiment limitation of the present invention.
The solid dispersion (1: 4) of embodiment 1. olmesartan medoxomils and polyvinylpyrrolidone and preparation
Getting 1g olmesartan medoxomil and 4g polyvinylpyrrolidone is dissolved in the methanol of 140ml, steam except that (vacuum pump decompression) methanol in Rotary Evaporators, to obtain solids scrapes and gets 35 ℃ of dry 24h in the rearmounted vacuum desiccator, pulverize 80 mesh sieves, promptly got the solid dispersion (1: 4) of olmesartan medoxomil and polyvinylpyrrolidone.The accumulative total dissolution is 84.97% during its 45min.
The solid dispersion (1: 4) of embodiment 2. olmesartan medoxomils and polyvinylpyrrolidone and preparation
Similarly, press the preparation method of embodiment 1, the mass ratio that dissolves olmesartan medoxomil and polyvinylpyrrolidone in an amount of ethanol respectively is 1: 0.8,1: 1,1: 2,1: 3,1: 4,1: 5,1: 6,1: 7,1: 8,1: 10,1: 20,1: 50,1: 80,1: 100,1: 130,1: 170 solids, reclaim ethanol in Rotary Evaporators (vacuum pump decompression) evaporation, collect solids, put and be dried to constant weight in the vacuum desiccator, pulverize 80～100 mesh sieves, promptly got the olmesartan medoxomil of various different proportionings and the solid dispersion of polyvinylpyrrolidone.
The solid dispersion (1: 2) of embodiment 3. olmesartan medoxomils and polyvinylpyrrolidone and preparation
Get 1g olmesartan medoxomil and 2g polyvinylpyrrolidone, put in the mortar, add 5ml acetone, make pastel, grind 30min, sulfuration bed drying is removed acetone, with gained solids crushing screening, promptly get the solid dispersion (1: 2) of olmesartan medoxomil and polyvinylpyrrolidone.The accumulative total dissolution is 81.25% during its 45min.
The solid dispersion (1: 8) of embodiment 4. olmesartan medoxomils and polyvinylpyrrolidone and preparation
Method one. get 5g olmesartan medoxomil and 40g polyvinylpyrrolidone, behind 900 dissolve with ethanols, spray drying is removed ethanol, gets powder of solid particles, crushing screening, promptly.The accumulative total dissolution is 86.13% during its 45min.
Method two. get 5g olmesartan medoxomil and 40g polyvinylpyrrolidone, behind 900 dissolve with methanol, the sulfuration bed is granulated dry, gets powder of solid particles, crushing screening, promptly.The accumulative total dissolution is 86.25% during its 45min.
Method three. get 5g olmesartan medoxomil and 40g polyvinylpyrrolidone, pulverize separately is crossed 100 mesh sieves, grinds the 35min that rubs behind the mixing in mortar, scrapes the material of getting after the grinding, and powder ground 80 mesh sieves, promptly.The accumulative total dissolution is 84.75% during its 45min.
The solid dispersion (1: 3) of embodiment 5. olmesartan medoxomils and poloxamer and preparation
Method one. get 1g olmesartan medoxomil and 3g poloxamer, after 110ml, 40 ℃ acetone and alcohol mixeding liquid (equal-volume is than mixing) dissolving, reduction vaporization reclaims acetone and alcohol mixeding liquid on Rotary Evaporators, collect solids, 40 ℃ of vacuum drying 10h, pulverize 80 orders, promptly got the solid dispersion (1: 3) of olmesartan medoxomil and poloxamer.The accumulative total dissolution is 82.20% during its 45min.
Method two. get the 1g olmesartan medoxomil with behind the 65ml acetone solution, add the fused solution thing of poloxamer in 65 ℃ under, fully stir and reduce pressure and make the acetone Ex-all, vacuum drying 24h, pulverizing, promptly.
The solid dispersion (1: 19) of embodiment 6. olmesartan medoxomils and poloxamer and preparation
Get the 19g poloxamer be heated to 60 ℃ make it be fused solution after, adding 1g olmesartan medoxomil stirs and reduces to room temperature gradually, and puts in-10 ℃ of refrigerators, makes it solidify the back and pulverizes, drying under reduced pressure, the solid dispersion (1: 19) that sieves and promptly get olmesartan medoxomil and poloxamer.The accumulative total dissolution is 89.71% during its 45min.
Embodiment 7.
Similarly, press the preparation method of embodiment 5 or 6, the mass ratio that can make olmesartan medoxomil and poloxamer respectively is 1: 0.9,1: 1,1: 2,1: 3.5,1: 5.5,1: 6,1: 7.5,1: 8,1: 10,1: 25,1: 50,1: 80,1: 100,1: 130,1: 170 a solids, and put and be dried to constant weight in the vacuum desiccator, pulverize 80～100 mesh sieves, promptly got the olmesartan medoxomil of various different proportionings and the solid dispersion of poloxamer.
The solid dispersion (1: 1) of embodiment 8. olmesartan medoxomils and Macrogol 3000 and preparation
Getting 1g olmesartan medoxomil and 1gPEG3000 is dissolved in the 100ml ethanol, reduction vaporization reclaims ethanol on Rotary Evaporators, scrapes and gets the collection solids, vacuum drying 20h, pulverize (crossing 80 mesh sieves), promptly get the solid dispersion (1: 1) of olmesartan medoxomil and Macrogol 3000.The accumulative total dissolution is 79.59% during its 45min.
The solid dispersion (1: 4.5) of embodiment 9. olmesartan medoxomils and Macrogol 4000 and preparation
Get the 1g olmesartan medoxomil, add 4.5g PEG4000 in the fused solution of 68 ℃ of heating in water bath, fully stir and make mix homogeneously, be cooled to 0 ℃ and make its curing, pulverized 80 mesh sieves, promptly get the solid dispersion (1: 4.5) of olmesartan medoxomil and PEG4000.The accumulative total dissolution is 82.55% during its 45min.
The solid dispersion (1: 30) of embodiment 10. olmesartan medoxomils and Polyethylene Glycol and preparation
Get 25gPEG10000 and 5g PEG1500 mixture, after 69 ℃ of heating in water bath make its whole fusions and whisk mix homogeneously, add the 1g olmesartan medoxomil, fully stir and make mix homogeneously, be cooled to 5 ℃ and make its curing, pulverize 60 mesh sieves, promptly got the solid dispersion (1: 30) of olmesartan medoxomil and Polyethylene Glycol (mixture of PEG10000 and PEG1500).The accumulative total dissolution is 91.04% during its 45min.
Embodiment 11.
Similarly, press the preparation method of embodiment 8,9 or 10, the mass ratio that can make the solid polyethylene glycol of olmesartan medoxomil and various different molecular weights respectively is 1: 0.7,1: 1.5,1: 3,1: 5,1: 6,1: 7,1: 9,1: 10,1: 15,1: 20,1: 35,1: 80,1: 99,1: 150,1: 180 a solids, and put and be dried to constant weight in the vacuum desiccator, pulverize 80～100 mesh sieves, promptly got the olmesartan medoxomil of various different proportionings and the solid dispersion of Polyethylene Glycol.
The solid dispersion (1: 3.5) of embodiment 12. olmesartan medoxomils and glyceryl monostearate and preparation
Method one: get 1g olmesartan medoxomil and 3.5g glyceryl monostearate and add in 95ml, 40 ℃ the ethanol, stirring makes dissolving fully, steam except that ethanol in Rotary Evaporators (vacuum pump decompression), or ethanol is removed in lyophilization, to obtain solids and pulverize 80 mesh sieves, promptly get the solid dispersion (1: 3.5) of olmesartan medoxomil and glyceryl monostearate.The accumulative total dissolution is 80.91% during its 45min.
Can make the solid dispersion of 1: 0.6,1: 1,1: 3,1: 4,1: 5,1: 5.5,1: 7 equal proportion with above-mentioned similar approach.
The solid dispersion (1: 6) of embodiment 13. olmesartan medoxomils and glyceryl monostearate and preparation
Method one: get 61～63 ℃ of 6g glyceryl monostearate heating in water bath and make it be fused liquid state, add the 1g olmesartan medoxomil, make mix homogeneously in 60～62 ℃ of abundant stirrings, place 0 ℃ to make curing, pulverize, and put 35 ℃ of dry 24h in the vacuum desiccator, and pulverized 80 mesh sieves, promptly get the solid dispersion (1: 6) of olmesartan medoxomil and glyceryl monostearate.The accumulative total dissolution is 85.11% during its 45min.
Method two: after getting 6g glyceryl monostearate heating in water bath to 62 and ℃ it being in a liquid state, it is added the solution of 1g olmesartan medoxomil in 75ml methanol, mixture is removed methanol in 55 ℃ of spray dryinges, the gained solids was pulverized 80 mesh sieves, promptly got the solid dispersion (1: 6) of Rimonabant and glyceryl monostearate.The accumulative total dissolution is 85.43% during its 45min.
Can make the solid dispersion of 1: 10,1: 12,1: 15,1: 40,1: 50,1: 60,1: 150 equal proportion with above-mentioned similar approach.
The solid dispersion (1: 2) of embodiment 14. olmesartan medoxomils and sucrose fatty acid ester and preparation
Method one: get 5g olmesartan medoxomil and 10g sucrose fatty acid ester (HLB=15) put in the mortar mix after, add 40ml acetone and make pastel, pastel is ground 1h, put vacuum drying oven and be dried to constant weight for 40 ℃, pulverize 80 mesh sieves, promptly got the solid dispersion (1: 2) of olmesartan medoxomil and sucrose fatty acid ester.The accumulative total dissolution is 80.68% during its 45min.
Method two: get the 1g olmesartan medoxomil and 2g sucrose fatty acid ester (HLB=17) is dissolved in the 120ml acetone, stirring 5min splits in the concentrating under reduced pressure instrument and reclaims acetone, collect solids, 40 ℃ of vacuum drying 10h, pulverize 80 orders, promptly got the solid dispersion (1: 2) of olmesartan medoxomil and poloxamer.The accumulative total dissolution is 80.93% during its 45min.
Can make the solid dispersion of 1: 1,1: 2.2,1: 3,1: 4,1: 5,1: 6,1: 7 equal proportion with above-mentioned similar approach.
The solid dispersion (1: 29) of embodiment 15. olmesartan medoxomils and polyoxyl stearate and preparation
Method one: get 29g polyoxyethylene stearate (40) ester heating in water bath and make it be fused liquid state for 51～53 ℃, add the 1g olmesartan medoxomil, fully stir and make mix homogeneously, place 5 ℃ to make curing, pulverize, and put 30 ℃ of dry 24h in the vacuum desiccator, and pulverized 80 mesh sieves, promptly get the solid dispersion (1: 29) of olmesartan medoxomil and polyoxyl stearate.The accumulative total dissolution is 91.79% during its 45min.
The solid dispersion (1: 2) of embodiment 16. olmesartan medoxomils and polyoxyl stearate and preparation
Get the 1g olmesartan medoxomil and 2g polyoxyl stearate ester is dissolved in the 135ml ethanol, after stirring, decompression recycling ethanol, gained solids are put 35 ℃ of dry 24h in the vacuum desiccator, pulverize 80 mesh sieves, promptly got the solid dispersion (1: 2) of olmesartan medoxomil and polyoxyl stearate.The accumulative total dissolution is 81.68% during its 45min.
Similarly, press the method for the foregoing description 15,16, the mass ratio that can make olmesartan medoxomil and polyoxyl stearate is 1: 1,1: 3,1: 5,1: 6,1: 10,1: 25,1: 35,1: 100,1: 165 a solid dispersion, off-white color or white yellow powder solid.(annotate: make the polyoxyl stearate heating be fused solution in 50～53 ℃, the 1g polyoxyl stearate can dissolve in the methanol of about 20ml or ethanol.)
The solid dispersion (1: 5) of embodiment 17. olmesartan medoxomils and polyoxyethylene castor oil and preparation
Get 1g olmesartan medoxomil and 5g polyoxyethylene castor oil put in the mortar mix after, add 25ml acetone and make pastel, pastel is ground 1h, put vacuum drying oven and be dried to constant weight for 35 ℃, pulverize 80 mesh sieves, promptly got the solid dispersion (1: 5) of olmesartan medoxomil and polyoxyethylene castor oil.The accumulative total dissolution is 83.38% during its 45min.
Can make the solid dispersion of 1: 0.7,1: 1,1: 2,1: 3,1: 3.5,1: 4.5,1: 6,1: 7,1: 8,1: 9,1: 10,1: 12 equal proportion with similar approach.
The solid dispersion (1: 4) of embodiment 18. olmesartan medoxomils and Polyethylene Glycol, polyoxyethylene castor oil and preparation
Getting the 1g olmesartan medoxomil is dissolved in the 75ml ethanol, add 1g polyethylene glycol 6000,3g polyoxyethylene castor oil in the ethanol of 60ml, fully stir, decompression makes the ethanol evaporation Ex-all, vacuum drying is pulverized, and promptly obtains the solid dispersion of olmesartan medoxomil and polyethylene glycol 6000, polyoxyethylene castor oil, wherein the mass ratio of olmesartan medoxomil and polyethylene glycol 6000, polyoxyethylene castor oil is 1: 4, and the accumulative total dissolution is 83.06% during its 45min.
The solid dispersion (1: 15) of embodiment 19. olmesartan medoxomils and poloxamer, glyceryl monostearate and preparation
Getting 10g poloxamer, 5g glyceryl monostearate simply mixes the back heating in water bath and makes it be fused liquid state for 59～61 ℃, fully stirring adds the 1g olmesartan medoxomil after making mix homogeneously, fully stir and make mix homogeneously, be cooled to 5 ℃ and make curing, pulverize, and put 35 ℃ of dry 24h in the vacuum desiccator, and pulverized 80 mesh sieves, promptly get the solid dispersion (1: 15) of olmesartan medoxomil and poloxamer, glyceryl monostearate.The accumulative total dissolution is 88.58% during its 45min.
The solid dispersion (2: 1: 10) of embodiment 20. olmesartan medoxomils, hydrochlorothiazide and poloxamer and preparation
Getting 10g poloxamer (407) heating in water bath makes it be fused liquid state for 65 ℃, add 2g olmesartan medoxomil, 1g hydrochlorothiazide, fully stir and make mix homogeneously, put refrigerator and make curing in-5 ℃, pulverize, and put 35 ℃ of dry 24h in the vacuum desiccator, and pulverized 80 mesh sieves, promptly get the solid dispersion (2: 1: 10) of olmesartan medoxomil, hydrochlorothiazide and poloxamer.The accumulative total dissolution is 83.87% during its 45min.
Embodiment 21. contains the tablet and the preparation of the solid dispersion (1: 3) of olmesartan medoxomil and polyvinylpyrrolidone
Olmesartan medoxomil/polyvinylpyrrolidone solid dispersion (1: 3) 80g
Mannitol 120g
Microcrystalline Cellulose 60g
Carboxymethyl starch sodium 8g (in disintegrating agent)
Sodium lauryl sulphate 1g
Pregelatinized Starch 18g (adding disintegrating agent)
Magnesium stearate 2g
Preparation method one (wet granulation): by above prescription, preceding four kinds of pressed powder mixings are also crossed 80 mesh sieves, be dissolved in the liquid wet granulation of 80% alcoholic solution with sodium lauryl sulphate, the system soft material, 20 mesh sieves are granulated, and in 40 ℃ of dryings, the back adds pregelatinized Starch and magnesium stearate mix homogeneously, 18 mesh sieve granulate, tabletting (3.2kg/cm 2) be made as 1000, every contains active ingredient and counts 20mg with olmesartan medoxomil, for orally using.The accumulative total dissolution is 83.75% during its 45min, and sheet base disintegration time is 157 seconds.
Preparation method two (dry granulation): the mannitol in the above-mentioned prescription; microcrystalline Cellulose; carboxymethyl starch sodium; the sodium lauryl sulphate adjuvant; pulverize; cross 100 mesh sieves; 85 ℃ through drying under reduced pressure more than 12 hours to constant weight; be cooled to room temperature at drying condition (in the exsiccator); take by weighing recipe quantity olmesartan medoxomil/polyvinylpyrrolidone solid dispersion and above-mentioned dry adjuvant; dry granulation behind the mix homogeneously (dry granulation machine); add pregelatinized Starch and magnesium stearate again; be compressed to 1000 behind the mix homogeneously; every contains active ingredient and counts 20mg with olmesartan medoxomil, for orally using.The accumulative total dissolution is 82.91% during its 45min.
In addition, also can adopt conventional packaging technique that the tablet of above-mentioned preparation is carried out coating (gastric solubleness film-coat or enteric coating) and handle, can obtain the coating diaphragm.
Embodiment 22.
Similarly, by above method, select suitable pharmaceutic adjuvant for use, can make respectively olmesartan medoxomil and poloxamer, with Polyethylene Glycol, with glyceryl monostearate, with polyoxyl stearate, with sucrose fatty acid ester, with the tablet of the solid dispersion of polyoxyethylene castor oil, the every content that can contain olmesartan medoxomil is 2mg～80mg; The content of preferred olmesartan medoxomil is 5mg～60mg; The content of preferred olmesartan medoxomil is 10mg～40mg; The content of preferred olmesartan medoxomil is 20mg.
Embodiment 23. contains the capsule and the preparation of the solid dispersion (1: 7) of olmesartan medoxomil and polyethylene glycol 6000
The solid dispersion of olmesartan medoxomil and polyethylene glycol 6000 (1: 7) 80g
Starch 100g
Pulvis Talci 1.5g
To be filled into behind above-mentioned three kinds of solids mixings in 1000 Capsuleses (gastric solubleness or enteric) promptly.Every contains active ingredient and counts 10mg with olmesartan medoxomil, for orally using.The accumulative total dissolution is 85.22% during capsule 's content 45min.
Embodiment 24. contains the capsule and the preparation of the solid dispersion (1: 4) of olmesartan medoxomil and sucrose fatty acid ester
The solid dispersion of olmesartan medoxomil and sucrose fatty acid ester (1: 4) 100g
Lactose 50g
Hydroxypropyl cellulose 50g
Carboxymethyl starch sodium 20g
Magnesium stearate 2g
Preparation: pulverized 80 mesh sieves after preceding four kinds of pressed powder equivalent of getting recipe quantity increase progressively mix homogeneously, mixing, to above-mentioned mixed-powder system soft material, 16 mesh sieves are granulated with 30% alcoholic solution, aeration-drying is filled into behind the 14 mesh sieve granulate in 1000 Capsuleses (gastric solubleness or enteric) promptly.Every contains active ingredient and counts 20mg with olmesartan medoxomil, for orally using.The accumulative total dissolution is 81.72% during capsule 's content 45min.
Embodiment 25. contain olmesartan medoxomil with the capsule and the preparation of polyoxyethylene castor oil solid dispersion (1: 5)
Olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5) 120g
Magnesium stearate 2g
By above prescription, two kinds of solids were pulverized in the rearmounted mixer of 80 mesh sieves, to be filled into behind the equivalent incremental manner mix homogeneously in 1000 Capsuleses (gastric solubleness or enteric) promptly.Every contains active ingredient and counts 20mg with olmesartan medoxomil, for orally using.The accumulative total dissolution is 84.11% during capsule 's content 45min.
Embodiment 26. contains the dry suspension and the preparation of olmesartan medoxomil and polyoxyl stearate solid dispersion (1: 3)
Olmesartan medoxomil/polyoxyethylene stearate (40) ester solid dispersion (1: 3) 16g
Lactose 50g
Mannitol 40g
Icing Sugar 55g
Hydroxypropyl emthylcellulose 5g (suspending agent)
Flavoring orange essence is an amount of
Dehydrated alcohol is an amount of
Make 100 bags altogether.
Preparation method 1: it is dry respectively that the first five of side's amount planted pressed powder, to reduce the water content in the solid powder, get an amount of dehydrated alcohol, cross 20 mesh sieve wet granulations, granulate is put in 45 ℃ of baking ovens dry, spray wine flavoring orange essence, granulate is distributed into 100 bags of aluminum plastic film bag packings, promptly gets every bag of dry suspension (sweet Fructus Citri tangerinae taste) that contains olmesartan medoxomil 40mg.
Preparation method 2: the above-mentioned pressed powder of recipe quantity is dry respectively, to reduce the water content in the solid powder, put the mixer moderate and increase progressively mix homogeneously, cross 100 mesh sieves, with 18 mesh sieve dry granulations, put 45 ℃ of oven dryings, spray wine flavoring orange essence, behind granulate, be distributed into 100 bags of aluminum plastic film bag packings, promptly get every bag of dry suspension (sweet Fructus Citri tangerinae taste) that contains olmesartan medoxomil 40mg.The accumulative total dissolution is 81.90% during its 45min.
Embodiment 27. contains the granule and the preparation of olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5)
Olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5) 12g
Lactose 65
Pregelatinized Starch 20g
Icing Sugar 35g
Carboxymethyl starch sodium-starch (2: 8) 35g
Sodium lauryl sulphate 1g
Steviosin is an amount of
Flavoring orange essence is an amount of
30% alcoholic solution is an amount of
Make 100 bags altogether.
Preparation method 1: the first six of getting recipe quantity planted and to be pulverized 80 mesh sieves after pressed powder equivalent increases progressively mix homogeneously, mixing, steviosin and flavoring orange essence are dissolved in an amount of 30% alcoholic solution, to above-mentioned mixed-powder system soft material, 16 mesh sieves are granulated, aeration-drying with this solution, 14 mesh sieve granulate, be distributed into 100 bags of aluminum plastic film bag packings, promptly get the granule that contains olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5), every bag contains olmesartan medoxomil 20mg (sweet Fructus Citri tangerinae taste).The accumulative total dissolution is 83.97% during its 45min.
Preparation method 2: the first six of getting recipe quantity planted and to be pulverized 80 mesh sieves after pressed powder equivalent increases progressively mix homogeneously, mixing, steviosin and flavoring orange essence are dissolved in the wetting agent of making wet granulation in an amount of 30% alcoholic solution, with the boiling granulating fluidized bed granulation, granulate, be distributed into 100 bags of aluminum plastic film bag packings, promptly contain the granule of olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5), every bag contains olmesartan medoxomil 20mg (sweet Fructus Citri tangerinae taste).
Embodiment 28. contains the soft capsule and the preparation of olmesartan medoxomil and glyceryl monostearate solid dispersion (1: 1)
Olmesartan medoxomil and glyceryl monostearate solid dispersion (1: 1) 20g
PEG400 240g
Glycerol 3g
Carboxymethyl starch sodium 5g
Make 1000 altogether.
Preparation method: get the olmesartan medoxomil of recipe quantity and glyceryl monostearate solid dispersion (1: 1), PEG400 and propylene glycol heating in water bath to 40 ℃ and stir and make dissolving fully, obtain adding carboxymethyl starch sodium behind the clear and bright solution, dissolving stirs, stand-by, this clear and bright solution will be added to as the content of soft capsule in the continuously automatic soft capsule production machine of punching type, select appropriate mould model, adopt pressing to be embedded in the ' Yanming ' capsules for clearing material film, 1000 soft capsules are made in mold pressing, every contains olmesartan medoxomil 10mg, for orally using.The accumulative total dissolution is 91.80% during its 45min.(also can adopt the dropping preparation method preparation)
(attached: the preparation of capsule material film, get gelatin 500g, arabic gum 80g, add 600～900ml distilled water, under room temperature, stir to quicken to make gelatin expansion post-heating to 55～60 ℃, make its fusion and filter, in filtrate, add 75g PEG400,370g glycerol, 10g glycine, mix homogeneously, decompression outgases to transparent glue solution does not have bubble, and repaste makes thickness even on smooth steel plate, heating makes surface moisture evaporation, is an elasticity, capsule material film that toughness is suitable.)
Embodiment 29. contains the drop pill and the preparation of olmesartan medoxomil and polyoxyethylene stearate (40) ester solid dispersion (1: 29)
Olmesartan medoxomil/polyoxyethylene stearate (40) ester solid dispersion (1: 29) 300g
Sodium lauryl sulphate 2g
Crospolyvinylpyrrolidone 5g
Make 10000 altogether.
Preparation method: get olmesartan medoxomil/polyoxyethylene stearate (40) ester solid dispersion (1: 29) heating in water bath to 53 of recipe quantity～55 ℃ complete fusion is in a liquid state, add recipe quantity sodium lauryl sulphate and crospolyvinylpyrrolidone, and fully stirring makes molten loosing in fused solution, stir, this fused solution is poured in the Materials hopper that drop pill drips the system machine, 55 ℃ of insulations, the water dropper of the suitable bore of selection drips makes 10000, splash in 4 ℃ the dimethicone, to be formed after, isolate drop pill, wiped clean, that is, every heavily about 30mg contains the about 1mg of olmesartan medoxomil.This drop pill can oral or sublingual administration use.The accumulative total dissolution is 91.55% during its 45min.
Embodiment 30. contains the drop pill and the preparation of olmesartan medoxomil and glyceryl monostearate solid dispersion (1: 2)
Olmesartan medoxomil/glyceryl monostearate solid dispersion (1: 2) 30g
Polyethylene glycol 6000 270g
Sodium carboxymethyl cellulose 10g
Make 10000 altogether.
Preparation method: the polyethylene glycol 6000 of getting recipe quantity is heated to 74 ℃ makes complete fusion be clear and bright liquid state, add recipe quantity olmesartan medoxomil and glyceryl monostearate solid dispersion (1: 2) and fully stir and make molten loosing in the mixture of liquid state, the sodium carboxymethyl cellulose that adds recipe quantity again, stir, this fused solution is poured in the Materials hopper that drop pill drips the system machine, 72 ± 3 ℃ of insulations, the water dropper of the suitable bore of selection drips makes 10000, splash in 4 ℃ the dimethicone, to be formed after, isolate drop pill, wiped clean, that is, every heavily about 31mg contains the about 1mg of olmesartan medoxomil.This drop pill can oral or sublingual administration use.The accumulative total dissolution is 92.74% during its 45min.
Further, above-mentioned drop pill branch can be packed in 250 Capsuleses (gastric solubleness or enteric) promptly, every capsules contains 40 drop pill, promptly get the drop pill capsule that contains olmesartan medoxomil and glyceryl monostearate solid dispersion (1: 2), every drop pill capsule contains active ingredient and counts 40mg with olmesartan medoxomil, for orally using.
Embodiment 31. contains the micropill and the preparation of olmesartan medoxomil and sucrose fatty acid ester solid dispersion (1: 1)
Olmesartan medoxomil/sucrose fatty acid ester (HLB=11) solid dispersion (1: 1) 40g
Lactose 250g
Cane sugar powder 50g
Hydroxypropyl emthylcellulose 10g (binding agent)
Sodium carboxymethyl cellulose 10g
80% ethanol water is an amount of
Hydroxypropyl emthylcellulose 5g (sealing coat)
Preparation method: by above prescription, the first five is planted the pressed powder mixing and crosses 80 mesh sieves, with 80% alcoholic solution wet granulation, the system soft material, by extruding-rolling circle equipment system micropill, granulate, oven dry, make micropill be straight spherical shape through about 0.6mm, promptly obtain containing the micropill of olmesartan medoxomil and sucrose fatty acid ester (HLB=11) solid dispersion (1: 1), further with hydroxypropyl methylcellulose with distilled water modulation into about 25% suspension, and fully grind homogenize after, at fluidized bed dryer, the sealing coat suspension is coated to above-mentioned containing on the pill core, after having applied the sealing coat suspension of aequum, with micropill bone dry in fluidized bed dryer, obtain the stomach dissolution type micropill of isolation coat, the accumulative total dissolution is 78.31% during its 45min.
Further, can be with the above-mentioned micropill that makes, in 1000 Capsuleses of packing (gastric solubleness or enteric), promptly get the pellet capsule that contains olmesartan medoxomil and sucrose fatty acid ester (HLB=11) solid dispersion (1: 1), every pellet capsule contains active ingredient and counts 20mg with olmesartan medoxomil, for orally using.
Embodiment 32. contains the micropill and the preparation of olmesartan medoxomil and polyvinylpyrrolidone solid dispersion (1: 1.3)
Olmesartan medoxomil and polyvinylpyrrolidone solid dispersion (1: 1.3) 23g
Pregelatinized Starch 5g
Celphere: microcrystalline Cellulose-starch micropill (commercial, 35 to 40 orders) 150g
Opadry (water solublity) an amount of (sealing coat)
Preparation: olmesartan medoxomil and polyvinylpyrrolidone solid dispersion (1: 1.3), pregelatinized Starch are modulated suspension into about 20% with 70% ethanol water, and fully grinding homogenizes to reduce the suspension particle diameter, obtain containing the medicine layer coating solution of active ingredient, at fluidized bed dryer, the suspension that ground is coated on the celphere of microcrystalline Cellulose-starch micropill, after having applied the medicine layer coating solution of aequum, it is made it bone dry in fluidized bed dryer, the micropill that obtains.
Further, with Opadry with distilled water modulation into about 24～26% suspension, and after fully grinding homogenizes, at fluidized bed dryer, the sealing coat suspension spray is coated to above-mentioned containing on the pill core, after having applied the sealing coat suspension of aequum, with micropill bone dry in fluidized bed dryer, obtain the stomach dissolution type micropill of isolation coat, the accumulative total dissolution is 81.21% during its 45min.
Annotate: behind the Opadry that has applied aequum, micropill can be added a small amount of Pulvis Talci to reduce electrostatic charge when dry in fluidized bed dryer.
Further, the above-mentioned micropill that makes can be divided in 1000 Capsuleses (gastric solubleness or enteric) of packing into, promptly get the pellet capsule that contains the 10mg olmesartan medoxomil, for orally using.
Embodiment 33. contains the oral fluid agent and the preparation of olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5)
Olmesartan medoxomil/polyoxyethylene castor oil solid dispersion (1: 5) 1.2g
Hydroxypropyl cellulose 2g
Xylitol 10g
Sodium lauryl sulphate 0.8g
Potassium dihydrogen phosphate/sodium hydrogen phosphate an amount of (pH buffer agent)
Steviosin is an amount of
Water adds to 100ml
Preparation method: above-mentioned material is dissolved in the 80ml water, stirs, add water to 100ml, fully stir and homogenizing, promptly get the oral fluid agent that contains olmesartan medoxomil and polyoxyethylene castor oil solid dispersion (1: 5).The accumulative total dissolution is 83.12% during its 45min.
Embodiment 34. contains the capsule and the preparation of the solid dispersion (2: 1: 10) of olmesartan medoxomil, hydrochlorothiazide and poloxamer
The solid dispersion of olmesartan medoxomil, hydrochlorothiazide and poloxamer (2: 1: 10) 130g
Starch 70g
Magnesium stearate 2g
Equivalent increased progressively mix homogeneously after above-mentioned three kinds of pressed powders were pulverized 80 mesh sieves, was filled in 1000 Capsuleses (gastric solubleness or enteric), promptly got the capsule that contains 20mg olmesartan medoxomil, 10mg hydrochlorothiazide, for orally using.
The solid dispersion and the preparation of embodiment 35. olmesartan medoxomils and glyceryl monostearate and carboxymethyl starch sodium
Olmesartan medoxomil 2
Glyceryl monostearate 10g
Carboxymethyl starch sodium 2g
Preparation method: get olmesartan medoxomil and glyceryl monostearate and be dissolved in 160ml, 40 ℃ the ethanol of heating in water bath, add carboxymethyl starch sodium, behind the stirring and evenly mixing on Rotary Evaporators reduction vaporization reclaim ethanol, collect solids, vacuum drying 15h, pulverize (crossing 80 mesh sieves), promptly get the solid dispersion of olmesartan medoxomil and glyceryl monostearate and carboxymethyl starch sodium.The accumulative total dissolution is 85.07% during its 45min.
Solid dispersion and the preparation of embodiment 36. olmesartan medoxomils and polyoxyethylene stearate (40) ester and PEG6000
Olmesartan medoxomil 2
Polyoxyethylene stearate (40) ester 6g
PEG6000 2g
Preparation method 1: three kinds of materials getting above-mentioned recipe quantity are dissolved in the 155ml dehydrated alcohol, stir back 40 ℃ and remove and reclaim ethanol under reduced pressure and obtain blocks of solid, put 24h in the vacuum constant temperature drying baker, take out after the embrittlement and pulverize, cross 80 mesh sieves, promptly get the solid dispersion of olmesartan medoxomil and polyoxyethylene stearate (40) ester and PEG4000.The accumulative total dissolution is 82.78% during its 45min.
Preparation method 2: get polyoxyethylene stearate (40) ester of above-mentioned recipe quantity and PEG4000 and mix back heating in water bath to 55～58 ℃ and make its complete fusion, stir, the olmesartan medoxomil that adds recipe quantity again, make molten loosing in the mixture of liquid state, fully mix, put refrigerator and spend the night for 0 ℃, pulverize, cross 80 mesh sieves, promptly get the solid dispersion of olmesartan medoxomil and polyoxyethylene stearate (40) ester and PEG4000.
Get the solid dispersion and the preparation of embodiment 37. olmesartan medoxomils and sucrose fatty acid ester and microcrystalline Cellulose
Olmesartan medoxomil 10
Sucrose fatty acid ester (HLB=12) 150g
Microcrystalline Cellulose 35g
Crospolyvinylpyrrolidone 5g
Preparation method: get above-mentioned material mixing, add 60% methanol-water solution 1000ml, grind 30min, 40 ℃ of pressure reducing and steaming solvents, collect solids, vacuum drying 12h is cooled to 0 ℃ of pulverizing (crossing 80 mesh sieves), promptly gets the solid dispersion of olmesartan medoxomil and sucrose fatty acid ester and microcrystalline Cellulose.The accumulative total dissolution is 86.24% during its 45min.
The solid dispersion and the preparation of embodiment 38. olmesartan medoxomils and polyoxyethylene castor oil and mannitol
Olmesartan medoxomil 2
Polyoxyethylene castor oil 6g
Mannitol 42g
Preparation method: get above-mentioned three kinds of pressed powders and add in the 900ml ethanol, fully stir and make its dissolving, 47 ℃ remove and reclaim ethanol under reduced pressure, collect solids, 35 ℃ of vacuum drying 24h pulverize (crossing 80 mesh sieves), promptly get the solid dispersion of olmesartan medoxomil and polyoxyethylene castor oil and mannitol.The accumulative total dissolution is 83.12% during its 45min.
The solid dispersion and the preparation of embodiment 39. olmesartan medoxomils and poloxamer and xylitol
Olmesartan medoxomil 5
Poloxamer 8g
Xylitol 37g
Preparation method: get above-mentioned three kinds of pressed powder pulverize separately and cross 120 mesh sieves, oven dry back equivalent increases progressively mix homogeneously, puts and grinds 1.5h in the mortar, takes out and pulverizes 80 mesh sieves, promptly get the solid dispersion of olmesartan medoxomil and poloxamer and xylitol, the accumulative total dissolution is 81.37% during its 45min.
The solid dispersion and the preparation of embodiment 40. olmesartan medoxomils, hydrochlorothiazide and polyvinylpyrrolidone and pregelatinized Starch
Olmesartan medoxomil 2g
Hydrochlorothiazide 1g
Polyvinylpyrrolidone 10g
Pregelatinized Starch 35g
Preparation method: get above-mentioned four kinds of pressed powder pulverize separately and cross 120 mesh sieves, oven dry back equivalent increases progressively mix homogeneously, put in the mortar and to grind 2h and take out and pulverized 80～100 mesh sieves, promptly get the solid dispersion of olmesartan medoxomil and polyvinylpyrrolidone and pregelatinized Starch, the accumulative total dissolution is 85.55% during its 45min.
Embodiment 41. gets the prepared solid dispersion of EXAMPLE Example 35, embodiment 36, embodiment 37, embodiment 38, embodiment 39, embodiment 40 respectively, as principal agent, select suitable pharmaceutic adjuvant for use, adopt appropriate preparation technology, mix with pharmaceutic adjuvant and be prepared into and disperse sheet, slow releasing tablet, enteric coatel tablets, effervescent tablet, oral cavity disintegration tablet, chewable tablet, hard capsule, soft capsule, micropill, granule, dry suspension, powder, for orally using.
Embodiment 42. embodiment 1 to embodiment 40 prepared compositions, solid dispersion preparing the application for the treatment of in the hypertensive medicine.

Claims (11)

1. the solid dispersion of an olmesartan medoxomil, it is characterized in that containing olmesartan medoxomil and carrier material, described carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil, and the quality ratio range of olmesartan medoxomil and carrier material is 1: (0.5～180).
2. the described solid dispersion of claim 1, the quality ratio range that it is characterized in that olmesartan medoxomil and carrier material is 1: (1～1 70);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～160);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～150);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (4～140);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (5～130);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (6～120);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (7～110);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (8～100);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (9～80);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (10～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～35);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～30);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～25);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～20).
3. prepare the method for claim 1 or 2 described solid dispersion, it comprises:
Get olmesartan medoxomil and carrier material, add solvent, in 20 ℃ to the solvent boiling point temperature range, stirring is dissolved or dispersed in the solvent olmesartan medoxomil and carrier material, from this mixture, remove behind the mix homogeneously and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil, and described solvent is selected from one or more in methanol, ethanol, the acetone.In above-mentioned preparation, remove and to desolvate and exsiccant method can be taked Rotary Evaporators to steam to remove, removes under reduced pressure, in the drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, heating, drying one or more; Or
Get carrier material, add olmesartan medoxomil in 50～90 ℃ after being heated to complete fusion, mix, after cooling is solidified it, pulverize, promptly obtain solid dispersion, wherein said chilling temperature is below 25 ℃, preferred below 0 ℃ (as-5 ℃,-10 ℃,-15 ℃,-18 ℃,-20 ℃,-25 ℃,-30 ℃ or the like), optionally can further solid dispersion drying under reduced pressure (comprising vacuum drying) be beneficial to pulverize and preserve, described carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more; Or
Get carrier material in 50～90 ℃ be heated to complete fusion after, add and use methanol, ethanol is or/and the solution of olmesartan medoxomil of acetone solution, mix, remove and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, in above-mentioned preparation, described remove desolvated and exsiccant method can be taked Rotary Evaporators to steam to remove, remove under reduced pressure, drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, in the heating, drying one or more; Or
Get carrier material and olmesartan medoxomil, put in the mortar and grind, 100～600 rev/mins of rotating speeds, milling time 10～150min, take out, cross 80～200 mesh sieves, promptly get solid dispersion of the present invention, wherein said carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil; Or
Olmesartan medoxomil and carrier material are made pastel with suitable liquid, pastel is ground, further remove and desolvate and drying, pulverize, promptly get the solid dispersion of olmesartan medoxomil and carrier material, wherein said liquid is selected from methanol, ethanol, in the acetone one or more, wherein said remove desolvated and drying can adopt and removes under reduced pressure, drying under reduced pressure (comprising vacuum drying), spray drying, lyophilization, fluid bed drying, heating, drying, air-dry or noble gas is dry or its combination in any method concentrates and dry, wherein said carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, described solvent is selected from methanol, ethanol, in the acetone one or more
In above-mentioned preparation method four and the method five, the mode of described grinding can be carried out in such as grinder, extruder, homogenizer or blade blender.
4. olmesartan medoxomil and one or more the solid dispersion that is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil is characterized in that it is made by following method:
Get olmesartan medoxomil and carrier material, add solvent, in 20 ℃ to the solvent boiling point temperature range, stirring is dissolved or dispersed in the solvent olmesartan medoxomil and carrier material, from this mixture, remove behind the mix homogeneously and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil, and described solvent is selected from one or more in methanol, ethanol, the acetone.In above-mentioned preparation, remove and to desolvate and exsiccant method can be taked Rotary Evaporators to steam to remove, removes under reduced pressure, in the drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, heating, drying one or more; Or
Get carrier material, add olmesartan medoxomil in 50～90 ℃ after being heated to complete fusion, mix, after cooling is solidified it, pulverize, promptly obtain solid dispersion, wherein said chilling temperature is below 25 ℃, preferred below 0 ℃ (as-5 ℃,-10 ℃,-15 ℃,-18 ℃,-20 ℃,-25 ℃,-30 ℃ or the like), optionally can further solid dispersion drying under reduced pressure (comprising vacuum drying) be beneficial to pulverize and preserve, described carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more; Or
Get carrier material in 50～90 ℃ be heated to complete fusion after, add and use methanol, ethanol is or/and the solution of olmesartan medoxomil of acetone solution, mix, remove and desolvate, and the dry solid dispersion that obtains with pulverizing, wherein said carrier material is selected from poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, in above-mentioned preparation, described remove desolvated and exsiccant method can be taked Rotary Evaporators to steam to remove, remove under reduced pressure, drying under reduced pressure, vacuum drying, lyophilization, spray drying, fluid bed drying, in the heating, drying one or more; Or
Get carrier material and olmesartan medoxomil, put in the mortar and grind, 100～600 rev/mins of rotating speeds, milling time 10～150min, take out, cross 80～200 mesh sieves, promptly get solid dispersion of the present invention, wherein said carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil; Or
Olmesartan medoxomil and carrier material are made pastel with suitable liquid, pastel is ground, further remove and desolvate and drying, pulverize, promptly get the solid dispersion of olmesartan medoxomil and carrier material, wherein said liquid is selected from methanol, ethanol, in the acetone one or more, wherein said remove desolvated and drying can adopt and removes under reduced pressure, drying under reduced pressure (comprising vacuum drying), spray drying, lyophilization, fluid bed drying, heating, drying, air-dry or noble gas is dry or its combination in any method concentrates and dry, wherein said carrier material is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, in the polyoxyethylene castor oil one or more, described solvent is selected from methanol, ethanol, in the acetone one or more
In above-mentioned preparation method four and the method five, the mode of described grinding can be carried out in such as grinder, extruder, homogenizer or blade blender.
5. claim 1,2 or 4 described solid dispersion contain application in the pharmaceutical preparation of olmesartan medoxomil, the application in the hypertensive medicine of preparation treatment in preparation.
6. a pharmaceutical composition contains claim 1,2 or 4 described solid dispersion and pharmaceutically suitable carrier, and wherein in unit formulation, the content of the olmesartan medoxomil that solid dispersion provided of olmesartan medoxomil is 1mg～100mg;
The content of preferred olmesartan medoxomil is 2mg～80mg;
The content of preferred olmesartan medoxomil is 5mg～60mg;
The content of preferred olmesartan medoxomil is 10mg～40mg;
The content of preferred olmesartan medoxomil is 20mg.
7. the method for preparing the described pharmaceutical composition of claim 6, it comprises olmesartan medoxomil and one or more solid dispersion and the pharmaceutically suitable carrier that is selected from polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil fully is mixed and made into acceptable any pharmaceutical dosage form on the pharmaceutics that preferred pharmaceutical dosage form is tablet, hard capsule, soft capsule, drop pill, pellet, granule, dry suspension, powder, oral fluid agent, injection.
8. prepare the method for the described pharmaceutical composition of claim 6, it comprises:
By adopting wet granulation or dry granulation to obtain granule or dry suspension behind the solid dispersion of olmesartan medoxomil of the present invention and the pharmaceutical carrier mix homogeneously, optionally further tabletting obtains tablet or the fill Capsules obtains capsule, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose includes but not limited to the following material as lubricant: magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate; Or
By obtaining dry suspension or powder behind the solid dispersion of olmesartan medoxomil and the pharmaceutical carrier mix homogeneously, optionally can further dry suspension or powder fill Capsules shell be obtained hard capsule, perhaps mix homogeneously obtains granule behind wet granulation or the dry granulation, to obtain hard capsule in the granule fill Capsules shell, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol, pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), include but not limited to following material: hydroxypropyl emthylcellulose as the suspending agent of dry suspension, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose includes but not limited to the following material as lubricant: magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate; Or
By obtaining soft capsule with dripping to make to seal with soft capsule material compacting of gelatin or capsule material glue behind the solid dispersion of olmesartan medoxomil and the suitable pharmaceutical carrier mix homogeneously, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: Liquid Macrogol, PEG400, Macrogol 600, soybean oil, Semen Maydis oil, other vegetable oil, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), described " soft capsule material compacting or the capsule material glue system of dripping are sealed " is meant and adopts pressing or dropping preparation method to prepare soft capsule, pressing is meant that the liquid or soft plastic state content that adopts press will contain solid dispersion wraps up formation preparation of soft capsule method with the compacting of capsule material film, can be pressed into different shapes and content content with different moulds, usually seal the capsule preparation with rotating the continuously automatic soft capsule production machine of rolling capsule machine or punching type automatically, dropping preparation method is meant the method that is equipped with soft capsule by a making mechanism, at a certain temperature, generally remain on more than 45 ℃, it is biphase utilizing capsule material glue and liquid content, after making a certain amount of capsule material glue with quantitative liquid content parcel, splash into that (condensed fluid can be a liquid paraffin in the another kind of not miscible condensed fluid, methyl-silicone oil, vegetable oil, in the kerosene any one), behind the capsule material glue condensation by contact liquid, owing to surface tension effects makes it to solidify the spherical soft capsule of formation; Or
By with olmesartan medoxomil and poloxamer, Polyethylene Glycol, glyceryl monostearate, after the solid dispersion melting mixing of polyoxyl stearate is even, or with olmesartan medoxomil and poloxamer, Polyethylene Glycol, glyceryl monostearate, after the mixture melting mixing of polyoxyl stearate is even, splash in the not miscible condensed fluid, shrink condensation and make drop pill, optionally drop pill can contain but be not limited to following material as disintegrating agent: sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, can contain but be not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth), described condensed fluid includes but not limited to dimethicone, liquid paraffin, vegetable oil (as Semen Maydis oil), kerosene obtains the drop pill capsule in the capsulae vacuus of optionally can further drop pill being packed into; Or
By with the solid dispersion of olmesartan medoxomil and suitable pharmaceutical carrier melting mixing evenly after, splash in the not miscible condensed fluid, shrink condensation and make drop pill, wherein pharmaceutical carrier includes but not limited to the following material as filler or diluent: cetomacrogol 1000, polyethylene glycol 1500, Macrogol 3000, Macrogol 4000, Polyethylene Glycol 5000, polyethylene glycol 6000, Polyethylene Glycol 7000, Polyethylene Glycol 8000, Polyethylene Glycol 9000, cetomacrogol 1000 0, poloxamer, stearic acid, sodium stearate, hydrogenated vegetable oil, include but not limited to following material: sodium carboxymethyl cellulose as disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pregelatinized Starch, corn starch, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, described condensed fluid includes but not limited to dimethicone, liquid paraffin, vegetable oil (as Semen Maydis oil), kerosene obtains the drop pill capsule in the capsulae vacuus of optionally can further drop pill being packed into; Or
By with behind the solid dispersion of olmesartan medoxomil and the suitable pharmaceutical carrier mix homogeneously, make the solid preparation of spherical or near-spherical, perhaps with the solid dispersion of olmesartan medoxomil and suitable pharmaceutical carrier dissolving or molten being dispersed in the liquid medium, and its deposition is coated on the surface of celphere and forms micropill, wherein the solid medicinal carrier includes but not limited to the following material as disintegrating agent: sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium, include but not limited to following material: polyvinylpyrrolidone as binding agent, starch slurry, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum, or the like, include but not limited to following material: sodium lauryl sulphate as surfactant, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth) obtains the drop pill capsule in the capsulae vacuus of optionally can further micropill being packed into; Or
By the solid dispersion of olmesartan medoxomil and water or aqueous liquid mixing are evenly formed oral administration solution or suspension; Or
By solid dispersion and suitable injection pharmaceutical carrier mix homogeneously with olmesartan medoxomil, can obtain injection by the injection preparation method, wherein pharmaceutical carrier includes but not limited to the following material as filler or excipient: water, mannitol, sorbitol, lactose, xylitol, fructose, dextran, glucose, sodium chloride.
Optionally, difference and the needs of guaranteeing the medicament quality according to pharmaceutical dosage form can also add other suitable pharmaceutic adjuvant in the above-mentioned preparation method.
9. the solid dispersion of an olmesartan medoxomil, contain olmesartan medoxomil, carrier material and other pharmaceutical carrier, wherein the quality ratio range of olmesartan medoxomil and carrier material is 1: (0.5～180), and described carrier material is selected from one or more in polyvinylpyrrolidone, poloxamer, Polyethylene Glycol, glyceryl monostearate, polyoxyl stearate, sucrose fatty acid ester, the polyoxyethylene castor oil; And described other pharmaceutical carrier includes but not limited to lactose, mannitol, sorbitol, microcrystalline Cellulose, starch, modified starch, dextrin, cyclodextrin and derivant thereof, calcium phosphate, sucrose, Polyethylene Glycol (various molecular weight polyethylene glycol), pregelatinized Starch, xylitol, fructose, maltose alcohol, dextran, glucose, calcium sulfate, calcium hydrogen phosphate as filler or diluent; Include but not limited to sodium carboxymethyl cellulose, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, pregelatinized Starch, corn starch, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose, carboxymethylcellulose calcium as disintegrating agent; Include but not limited to sodium lauryl sulphate, sodium tetradecyl sulfate, sodium hexadecyl sulfate, sodium stearyl sulfate, Polysorbate (Polysorbate of various models), fatty acid Pyrusussuriensis smooth (the fatty acid Pyrusussuriensis of various models is smooth) as surfactant; Include but not limited to hydroxypropyl emthylcellulose, ethyl cellulose, arabic gum, xanthan gum, sodium carboxymethyl cellulose as suspending agent, or the like; Include but not limited to methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, gelatin, guar gum, xanthan gum as binding agent; Include but not limited to magnesium stearate, stearic acid, Pulvis Talci, stearyl fumarate as lubricant.
10. the described solid dispersion of claim 9, wherein the quality ratio range of olmesartan medoxomil and carrier material is 1: (1～170);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～160);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～150);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (4～140);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (5～130);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (6～120);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (7～110);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (8～100);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (9～80);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (10～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～60);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (0.5～35);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (1～30);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (2～25);
The quality ratio range of preferred olmesartan medoxomil and carrier material is 1: (3～20).
11. prepare the method for claim 9 or 10 described solid dispersion, it comprises olmesartan medoxomil, carrier material and other pharmaceutical carrier fully is mixed and made into any pharmaceutical dosage form of acceptable on the pharmaceutics that preferred pharmaceutical dosage form is tablet, hard capsule, soft capsule, drop pill, pellet, granule, dry suspension, powder, oral fluid agent, injection.
CN 200710112373 2007-06-12 2007-06-12 Solid olmesartan medoxmil dispersion and its prepn and medicinal application Pending CN101066264A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200710112373 CN101066264A (en) 2007-06-12 2007-06-12 Solid olmesartan medoxmil dispersion and its prepn and medicinal application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200710112373 CN101066264A (en) 2007-06-12 2007-06-12 Solid olmesartan medoxmil dispersion and its prepn and medicinal application

Publications (1)

Publication Number Publication Date
CN101066264A true CN101066264A (en) 2007-11-07

Family

ID=38879044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200710112373 Pending CN101066264A (en) 2007-06-12 2007-06-12 Solid olmesartan medoxmil dispersion and its prepn and medicinal application

Country Status (1)

Country Link
CN (1) CN101066264A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101919801A (en) * 2009-07-14 2010-12-22 无锡健而乐医药科技有限公司 Solid effervescent mixture for oral absorption
CN102028663A (en) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 Stable olmesartan medoxomil solid preparation
CN102119930A (en) * 2010-07-13 2011-07-13 福建天泉药业股份有限公司 Olmesartan medoxomil tablets and preparation method thereof
CN102133192A (en) * 2011-03-18 2011-07-27 海南美兰史克制药有限公司 Candesartan cilexetil lipid nanoparticle solid preparation
CN102238941A (en) * 2008-09-17 2011-11-09 迈兰实验室公司 Granulates, process for preparing them and pharmaceutical products containing them
WO2011083112A3 (en) * 2010-01-05 2011-12-29 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
CN102655856A (en) * 2009-06-19 2012-09-05 成药技术Ip控股（泽西）有限公司 Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
WO2012159511A1 (en) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
CN103917485A (en) * 2011-09-21 2014-07-09 株式会社Bio-Synectics Method for preparing nano particles
CN104173302A (en) * 2014-08-06 2014-12-03 上海信谊百路达药业有限公司 Olmesartan medoxomil tablet and preparation method thereof
CN104721147A (en) * 2015-04-03 2015-06-24 海南海力制药有限公司 Azilsartan solid dispersion as well as preparation method and medicament composition thereof
CN105147636A (en) * 2015-08-18 2015-12-16 上海韬鸿化工科技有限公司 Rosuvastatin calcium capsule and preparation method thereof
WO2016000608A1 (en) * 2014-07-01 2016-01-07 深圳信立泰药业股份有限公司 Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same
CN105663070A (en) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 Medicine composition containing olmesartan medoxomi I and preparation method thereof
CN107303278A (en) * 2016-04-25 2017-10-31 成都海创药业有限公司 A kind of solid dispersions of HC 1119 and preparation method thereof
EP3146962A4 (en) * 2014-05-23 2017-11-29 Shenzhen Salubris Pharmaceuticals Co., Ltd Allisartan isoproxil solid dispersion and pharmaceutical composition thereof
CN111214449A (en) * 2020-03-02 2020-06-02 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof
CN115887393A (en) * 2022-10-31 2023-04-04 修正药业集团股份有限公司 Olmesartan medoxomil tablet and preparation method thereof

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238941A (en) * 2008-09-17 2011-11-09 迈兰实验室公司 Granulates, process for preparing them and pharmaceutical products containing them
CN102655856A (en) * 2009-06-19 2012-09-05 成药技术Ip控股（泽西）有限公司 Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
CN101919801A (en) * 2009-07-14 2010-12-22 无锡健而乐医药科技有限公司 Solid effervescent mixture for oral absorption
CN101919801B (en) * 2009-07-14 2012-10-17 无锡健而乐医药科技有限公司 Solid effervescent mixture for oral absorption
WO2011083112A3 (en) * 2010-01-05 2011-12-29 Ratiopharm Gmbh Solid oral dosage form containing olmesartan medoxomil
CN102119930A (en) * 2010-07-13 2011-07-13 福建天泉药业股份有限公司 Olmesartan medoxomil tablets and preparation method thereof
CN102119930B (en) * 2010-07-13 2013-01-30 福建天泉药业股份有限公司 Olmesartan medoxomil tablets and preparation method thereof
CN102028663B (en) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 Stable olmesartan medoxomil solid preparation
CN102028663A (en) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 Stable olmesartan medoxomil solid preparation
CN102133192B (en) * 2011-03-18 2012-06-27 海南美兰史克制药有限公司 Candesartan cilexetil lipid nanoparticle solid preparation
CN102133192A (en) * 2011-03-18 2011-07-27 海南美兰史克制药有限公司 Candesartan cilexetil lipid nanoparticle solid preparation
CN103260605B (en) * 2011-05-23 2015-07-01 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
WO2012159511A1 (en) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
CN103260605A (en) * 2011-05-23 2013-08-21 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
CN103917485B (en) * 2011-09-21 2016-10-19 株式会社Bio-Synectics Nanometer grain preparation method
CN103917485A (en) * 2011-09-21 2014-07-09 株式会社Bio-Synectics Method for preparing nano particles
EP3146962A4 (en) * 2014-05-23 2017-11-29 Shenzhen Salubris Pharmaceuticals Co., Ltd Allisartan isoproxil solid dispersion and pharmaceutical composition thereof
CN105232489B (en) * 2014-07-01 2019-06-11 深圳信立泰药业股份有限公司 A kind of A Lishatan ester solid dispersions and the pharmaceutical composition containing the solid dispersions
WO2016000608A1 (en) * 2014-07-01 2016-01-07 深圳信立泰药业股份有限公司 Allisartan isoproxil solid dispersion and pharmaceutical composition comprising same
CN105232489A (en) * 2014-07-01 2016-01-13 深圳信立泰药业股份有限公司 Allisartan isoproxil solid dispersion and medicine composition containing allisartan isoproxil solid dispersion
JP2017519789A (en) * 2014-07-01 2017-07-20 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｓａｌｕｂｒｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ Risartan isoproxil solid dispersion and pharmaceutical composition containing the solid dispersion
CN104173302A (en) * 2014-08-06 2014-12-03 上海信谊百路达药业有限公司 Olmesartan medoxomil tablet and preparation method thereof
CN105663070A (en) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 Medicine composition containing olmesartan medoxomi I and preparation method thereof
CN104721147A (en) * 2015-04-03 2015-06-24 海南海力制药有限公司 Azilsartan solid dispersion as well as preparation method and medicament composition thereof
CN105147636A (en) * 2015-08-18 2015-12-16 上海韬鸿化工科技有限公司 Rosuvastatin calcium capsule and preparation method thereof
CN105147636B (en) * 2015-08-18 2018-12-11 杭州富阳鼎创科技有限公司 Rosuvastatin calcium capsule and preparation method thereof
CN107303278A (en) * 2016-04-25 2017-10-31 成都海创药业有限公司 A kind of solid dispersions of HC 1119 and preparation method thereof
CN107303278B (en) * 2016-04-25 2020-11-13 成都海创药业有限公司 HC-1119 solid dispersion and preparation method thereof
CN111214449A (en) * 2020-03-02 2020-06-02 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof
CN111214449B (en) * 2020-03-02 2021-09-07 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof
CN115887393A (en) * 2022-10-31 2023-04-04 修正药业集团股份有限公司 Olmesartan medoxomil tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
CN101066264A (en) Solid olmesartan medoxmil dispersion and its prepn and medicinal application
CN101040855A (en) Compound including rimonabant and poloxamer, solid dispersion and the preparation and the application of the medicine
CN1154490C (en) Celecoxib compositions
CN1230179C (en) Micronized eplerenone compositions
CN1212838C (en) Controlled-release dosage forms comprising zolpidem or salt thereof
CN1194687C (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
CN101039657A (en) Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose
CN1882346A (en) Solid dispersion or medicinal solid dispersion preparation of phenylalanine derivative
CN1106608A (en) Controlled release preparation containing a salt of morphine
CN1627959A (en) Pharmaceutical compositions for hepatitis C viral protease inhibitors
CN1087262A (en) Controlied release oxycodone compositions
CN1874761A (en) Sustained release dosage forms of ziprasidone
CN1748675A (en) Composition of rheinic acid compounds and preparing method and use for treating diabetes
CN1547467A (en) Compositions containing itraconazole and their preparation methods
CN87103284A (en) Novel pharmaceutical preparation for oral administration
CN1418089A (en) Pharmaceutical composition of glycogen phosphorylase inhibitors
CN1518442A (en) Pharmaceutical compositions comprising cyclosporin
CN101032464A (en) Combination containing rimonabant and polyvinyl pyrrolidone, solid dispersion and the preparing and medicine application thereof
CN101068550A (en) Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
CN1655765A (en) Sustained release pharmaceutical preparations and methods for producing the same
CN1681479A (en) Pharmaceutical compositions of semi-ordered drugs and polymers
CN1771973A (en) Composite medicine containing nonsteroidal anti-inflammatory analgetic and its prepn
CN1823805A (en) Ground erythromycin enteric micropill and its preparation method
CN101049308A (en) Solid dispersion containing rimonabant and polyethyleneglycol, preparation and medication application
CN1569156A (en) Medicament for treating cardiovascular and cerebrovascular disease and its preparation method and quality control method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071107